

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83516 A1

(51) International Patent Classification⁷: **C07K 1/14**,
14/47, 14/475, A61K 38/16, 38/17, 38/18, C12N 5/10,
15/12, 15/63, 15/64

MA 02113 (US). **HUNTER, Dale** [US/US]; 34 Green
Lodge Street, Canton, MA 02021 (US).

(21) International Application Number: PCT/US01/13943

(74) Agent: **MYERS, Louis**; Fish & Richardson P.C., 225
Franklin Street, Boston, MA 02110 (US).

(22) International Filing Date: 1 May 2001 (01.05.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/200,863 1 May 2000 (01.05.2000) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 60/200,863 (CON)
Filed on 1 May 2000 (01.05.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **MASSA-
CHUSETTS GENERAL HOSPITAL** [US/US]; Building
149, Suite 1101, 13th Street, Charleston, MA 02129 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BURGESON,**
Robert, E. [US/US]; 103 Appleton #4, Boston, MA 02116
(US). **BRUNKEN, William** [US/US]; 140 Commonwealth
Avenue, Chestnut Hill, MA 02167 (US). **CHAMPLAUD,**
Marie-France [US/US]; 23 Sheafe Street #3F, Boston,

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: LAMININ 15 AND USES THEREOF

(57) Abstract: The present invention features a novel member of the laminin family, i.e., laminin 15, the methods of making these molecules, and the methods of using these molecules in treating neural disorders, e.g., retinal disorders.



WO 01/83516 A1

LAMININ 15 AND USES THEREOF

Background of the Invention

Laminins are large heterotrimeric glycoproteins of the extracellular matrix. Each laminin heterotrimer is composed of an α , a β , and a γ chain, chosen from a number of possible homologues of each chain. Currently, eleven laminin chains have been identified: five α chains, three β chains, and three γ chains (Timpl (1996) *Curr Opin Cell Biol* 8: 618-624).

Summary of the Invention

The invention is based, in part, on the discovery of a novel member of the laminin family, laminin 15. Accordingly, the invention features a purified or isolated preparation, a recombinant preparation, or a composition of laminin 15, which includes laminin chains $\alpha 5$, $\beta 2$, and $\gamma 3$. In a preferred embodiment, the laminin 15 is a trimer of an $\alpha 5$, $\beta 2$, and $\gamma 3$ chain. In a preferred embodiment the laminin 15 is human laminin 15.

In a preferred embodiment the $\alpha 5$ chain has a molecular weight of 380 kD, or 330 kD, the $\beta 2$ chain has a molecular weight of 190 kD or 170 kD, the $\gamma 3$ chain has a molecular weight of 220 kD, 200 kD or 170 kD.

In another preferred embodiment, the $\alpha 5$ chain is reactive with or specifically binds an $\alpha 5$ -specific antibody, e.g., the mouse monoclonal antibody 4C7 (Engvall et al. (1986) *J Cell Biol* 103:2457-2465), or an antibody of the same laminin chain-specificity, e.g., one which can compete for the 4C7 epitope. In another preferred embodiment, the $\beta 2$ chain is reactive with or specifically binds a $\beta 2$ specific antibody, e.g., a guinea pig polyclonal GPI (Sanes et al. (1990) *J Cell Biol* 111:1685-1699), mouse monoclonal C4 (Sanes et al. (1983) *Cold Spring Harb Symp Quant Biol* 48: 667-678), or an antibody of the same laminin chain-specificity, e.g., one which can compete for the GPI or C4 epitope. In another preferred embodiment, the $\gamma 3$ chain is reactive with or specifically binds $\gamma 3$ specific a antibody, e.g., the rabbit antibody R16 or the rabbit antibody R21 (Koch et al. (1999) *J Cell Biol* 145: 605-618), or an antibody of the same laminin chain specificity, e.g., one which competes for the R16 or R21 binding site.

In yet another preferred embodiment, the $\alpha 5$ chain has the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4. In a preferred embodiment, the $\alpha 5$ chain is at least 60%,

65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% homologous to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4. In a preferred embodiment, the $\alpha 5$ chain differs from the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, by at least one, but less than 5, 10, 15 amino acid residues, e.g., by at least one, but less than 5, 10, 15 non-essential amino acid residues. Preferably, the $\alpha 5$ chain retains the ability to form a heterotrimer with the $\beta 2$ chain and the $\gamma 3$ chain.

In another preferred embodiment, the $\beta 2$ chain has the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 8. In a preferred embodiment, the $\beta 2$ chain is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% homologous to the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 8. In a preferred embodiment, the $\beta 2$ chain differs from the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 8, by at least one, but less than 5, 10, 15 amino acid residues, e.g., by at least one, but less than 5, 10, 15 non-essential amino acid residues. Preferably, the $\beta 2$ chain retains the ability to form a heterotrimer with the $\alpha 5$ chain and the $\gamma 3$ chain.

In another preferred embodiment, the $\gamma 3$ chain has the amino acid sequence of SEQ ID NO: 10. In a preferred embodiment, the $\gamma 3$ chain is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% homologous to the amino acid sequence of SEQ ID NO: 10. In a preferred embodiment, the $\gamma 3$ chain differs from the amino acid sequence of SEQ ID NO: 10, by at least one, but less than 5, 10, 15 amino acid residues, e.g., by at least one, but less than 5, 10, 15 non-essential amino acid residues. Preferably, the $\gamma 3$ chain retains the ability to form a heterotrimer with the $\alpha 5$ chain and the $\beta 2$ chain.

In another aspect, the invention features, a purified or isolated preparation, a recombinant preparation, or composition of laminin 15, which includes laminin chains $\alpha 5$, $\beta 2$, $\gamma 3$. In a preferred embodiment, the laminin 15 is a trimer of an $\alpha 5$, $\beta 2$, and $\gamma 3$ chain. In a preferred embodiment, the laminin 15 is human laminin 15.

The laminin chains of any laminin as disclosed herein can be the initial translation product or a degradation product, e.g., a naturally occurring degradation product of a laminin chain.

In another aspect, the invention features an isolated nucleic acid, e.g., DNA, RNA or cDNA encoding laminin 15, i.e., which encodes $\alpha 5$, $\beta 2$, or $\gamma 3$. The isolated nucleic acid can be a combination of nucleic acids each encoding one or more laminin 15 chains or a single nucleic acid, e.g., if in a vector, one or more of the chains can be in one vector or each chain

can be in a separate vector. The $\alpha 5$ can be, e.g., any $\alpha 5$ chain described herein. In a preferred embodiment, the nucleic acid encoding the $\alpha 5$ chain has the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3. In a preferred embodiment, the nucleic acid encoding the $\alpha 5$ chain has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% homology, or has the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3. In another preferred embodiment, the nucleic acid encoding the $\alpha 5$ chain hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3. The $\beta 2$ chain can be, e.g., any $\beta 2$ chain described herein. In a preferred embodiment, the nucleic acid encoding the $\beta 2$ chain has the nucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 7. In a preferred embodiment, the nucleic acid encoding the $\beta 2$ chain has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% homology, or has the nucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 7. In another preferred embodiment, the nucleic acid encoding the $\beta 2$ chain hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 7. The $\gamma 3$ chain can be, e.g., any $\gamma 3$ chain described herein. In a preferred embodiment, the nucleic acid encoding the $\gamma 3$ chain has the nucleotide sequence of SEQ ID NO: 9. In a preferred embodiment, the nucleic acid encoding the $\gamma 3$ chain has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% homology, or has the nucleotide sequence of SEQ ID NO: 9. In another preferred embodiment, the nucleic acid encoding the $\gamma 3$ chain hybridizes, e.g., hybridizes under stringent conditions, to the nucleotide sequence of SEQ ID NO: 9.

In a preferred embodiment, the isolated nucleic acid can be expressed in one or more vectors, e.g., an expression vector or expressed directly in a cell. A vector (or vectors) containing a sequence corresponding to the sequence of the isolated nucleic acid can express the isolated nucleic acid in a suitable cell or a suitable in vitro environment.

In another aspect, the invention features producing laminin 15 from a cell transfected with nucleic acid encoding a laminin 15, e.g., a laminin 15 described herein.

In another aspect, the invention features producing laminin 15 from a cell transfected with nucleic acid which encodes one or more of an $\alpha 5$ chain, a $\beta 2$ chain and/or a $\gamma 3$ chain, e.g., a nucleic acid described herein.

In another aspect, the invention features a recombinant laminin 15 which can be produced, e.g., by expressing the laminin chains of laminin 15 in a suitable cell host and under a condition suitable for the laminin chains to form laminin 15.

In a preferred embodiment, the laminin 15 differs from a naturally occurring laminin 15 by at least 1, but less than 5, 10, or 15 amino acid residues. In another embodiment, one, two, or each laminin chain of a laminin, differs from its naturally occurring counterpart by at least 1, but less than 5, 10, or 15 amino acid residues.

5 The invention provides a method for treating a disorder associated with abnormal functions of synapses, e.g., insufficient stability, viability, formation, and/or defective organization of synapses. The method comprises administering to a subject an effective amount of: laminin 15, laminin 14, or a combination thereof.

10 The invention further provides a method for modulating retinal development, e.g., in the subretinal space, in the interphotoreceptor matrix, and/or in the outer plexiform layer. The method comprises administering to a subject an effective amount of: laminin 15, laminin 14, or a combination thereof.

15 The invention provides a method for treating a disorder associated with: insufficient neural cell growth, healing and regeneration, e.g., axon outgrowth; a disorder associated with abnormal subretinal space or interphotoreceptor matrix (IPM) such as inadequate stability of IPM; a disorder associated with retina contact, continuity, and/or adhesion; a disorder associated with abnormal and/or insufficient formation of synapses; a disorder associated with viability of a neural cell, e.g., photoreceptor or an element thereof, e.g., outer segment, inner segment, cell body, and/or synapses. The method comprises administering to a subject
20 an effective amount of laminin 15, laminin 14, or a combination thereof.

 Another feature of the present invention provides a method of treating a disorder associated with retinal abnormality, e.g., rod dystrophy, rod-cone dystrophy, macular degeneration, retinitis pigmentosa, or retinal detachment. The method includes administering to a subject an effective amount of: laminin 15, laminin 14, or a combination thereof.

25 Another feature of the present invention provides a method of inducing neural cell growth and/or regeneration, e.g., axon outgrowth. The method includes administering to a subject an effective amount of laminin 15, laminin 14, or a combination thereof. In a preferred embodiment, the method can be used to induce neural cell growth or regeneration in the central nervous system (CNS) and/or the peripheral nervous system (PNS).

30 In a preferred embodiment, the method includes administering to a wound an effective amount of: laminin 15, laminin 14, or a combination thereof.

 Still another feature of the invention provides a method of promoting a condition,

e.g., promoting retina inter-photoreceptor matrix stability; promoting the production, stability, and/or development of a retina photoreceptor or an element thereof, e.g., outer segment, inner segment, cell body, and/or synapses; promoting retinal contact, continuity, and/or adhesion; promoting the stability of synapses; and/or promoting the formation of synapses. The method includes administering an effective amount of: laminin 15, laminin 14, or a combination thereof.

Another feature of the invention provides a method for preparing an implant. For example, a method of preparing an implantable tip, an implantable catheter, a retinal implant, a timed releasing device, a neural cell growth guide, an artificial tissue, an implant of the central nervous system, or an implant of the peripheral nervous system. The method includes contacting, e.g., coating or incubating, the implant with laminin 15. In a preferred embodiment, laminin 15, laminin 14, or combinations thereof, can be used for treatment of a damaged eye, e.g., to increase photosensitivity in an eye, e.g., by implanting a tip coated with laminin 15, laminin 14, or a combination thereof, into the eye.

In a preferred embodiment, the implant is a subretinal implant, e.g., subretinal microphotodiodes, a visual prosthesis, e.g., a photoreceptive prosthesis (e.g., as reviewed in Peachey, *J Rehabil Res Dev* (1999) 36(4):371-6), an implant for photoreceptor replacement, a phototransistor, or a subretinally implanted microphotodiode array (MPDA) implant. Such implants are described in Zrenner et al. (1997) *Ophthalmic Res* 29(5):269-80; Zrenner et al. (1999) *Vision Res* 39(15):2555-67, or in the abstract entitled "Can Subretinal Microphotodiodes Successfully Replace Degenerated photoreceptors?" submitted by E. Zrenner et al. at the Vision Research Conference held on May 9, 1998. An example of a corneal keratoprosthesis (the Aachen-Keratoprosthesis) is described in Kompa et al. (2000) *Int J Artif Organs* 23(5):345-8.

A method of evaluating a compound for the ability to interact with, e.g., bind, a subject laminin 15 is provided. The method includes: contacting the compound with the subject laminin 15; and evaluating ability of the compound to interact with, e.g., to bind or form a complex with the subject laminin 15. This method can be performed in vitro, e.g., in a cell free system, or *in vivo*. This method can be used to identify naturally occurring molecules which interact with subject laminin 15. It can also be used to find natural or synthetic inhibitors of subject laminin 15. Screening methods are discussed in more detail below.

In one embodiment, an assay is a cell-based assay in which a cell which expresses laminin 15 or biologically active portion thereof is contacted with a test compound, and the ability of the test compound to modulate laminin 15 activity is determined.

5 The ability of the test compound to modulate laminin 15 binding to a compound, e.g., a laminin 15 substrate, or to bind to laminin 15, can also be evaluated.

Soluble and/or membrane-bound forms of isolated proteins (e.g., laminin 15 or biologically active portions thereof can be used in the cell-free assays of the invention. When membrane-bound forms of the protein are used, it may be desirable to utilize a solubilizing agent. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, 3-[(3-cholamidopropyl)dimethylamminio]-l-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl) dimethylamminio]-2-hydroxy-l-propane sulfonate (CHAPSO), or N-dodecyl-N, N-dimethyl-3-ammonio-1 -propane sulfonate.

15 Cell-free assays involve preparing a reaction mixture of the target gene protein and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex that can be removed and/or detected.

In a preferred embodiment, the assay includes contacting laminin 15 or biologically active portion thereof with a known compound which binds laminin 15 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with laminin 15, wherein determining the ability of the test compound to interact with laminin 15 includes determining the ability of the test compound to preferentially bind to laminin 15 or biologically active portion thereof, or to modulate the activity of a target molecule, as compared to the known compound.

25 In another aspect, the invention provides, a method of determining if a subject is at risk for a disorder, e.g., a disorder described herein.

In a preferred embodiment, the disorder is related to a lesion in or the misexpression of a gene which encodes one or more of a laminin 15 chain, e.g., one or more of an $\alpha 5$ chain, the $\beta 2$ chain, and/or $\gamma 3$ chain.

30 Such disorders include, e.g., a disorder associated with the misexpression of a laminin 15 chain, a disorder associated with the central nervous system and/or the peripheral nervous system, a retinal disorder.

The method includes one or more of the following:

detecting, in a tissue of the subject, the presence or absence of a mutation which affects the expression of one or more of a laminin 15 chain gene, e.g., one or more of an $\alpha 5$ chain, the $\beta 2$ chain, or $\gamma 3$ chain, or detecting the presence or absence of a mutation in a region which controls the expression of the gene, e.g., a mutation in the 5' control region;

detecting, in a tissue of the subject, the presence or absence of a mutation which alters the structure one or more of a laminin 15 chain gene, e.g., one or more of an $\alpha 5$ chain, the $\beta 2$ chain, or $\gamma 3$ chain gene;

detecting, in a tissue of the subject, the misexpression of one or more of a laminin 15 chain gene, e.g., one or more of an $\alpha 5$ chain, the $\beta 2$ chain, or $\gamma 3$ chain gene, at the mRNA level, e.g., detecting a non-wild type level of a mRNA;

detecting, in a tissue of the subject, the misexpression of the gene, at the protein level, e.g., detecting a non-wild type level of laminin 15.

In preferred embodiments the method includes: ascertaining the existence of at least one of: a deletion of one or more nucleotides from one or more of a laminin 15 chain gene, e.g., one or more of an $\alpha 5$ chain, the $\beta 2$ chain, or $\gamma 3$ chain gene; an insertion of one or more nucleotides into the gene, a point mutation, e.g., a substitution of one or more nucleotides of the gene, a gross chromosomal rearrangement of the gene, e.g., a translocation, inversion, or deletion.

For example, detecting the genetic lesion can include: (i) providing a probe/primer including an oligonucleotide containing a region of nucleotide sequence which hybridizes to a sense or antisense sequence from SEQ ID NO: or naturally occurring mutants thereof or 5' or 3' flanking sequences naturally associated with one or more of a laminin 15 chain gene, e.g., one or more of an $\alpha 5$ chain, the $\beta 2$ chain, or $\gamma 3$ chain gene; (ii) exposing the probe/primer to nucleic acid of the tissue; and detecting, by hybridization, e.g., *in situ* hybridization, of the probe/primer to the nucleic acid, the presence or absence of the genetic lesion.

In preferred embodiments detecting the misexpression includes ascertaining the existence of at least one of: an alteration in the level of a messenger RNA transcript of one or more of a laminin 15 chain gene, e.g., one or more of an $\alpha 5$ chain, the $\beta 2$ chain, or $\gamma 3$ chain gene; the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene; or a non-wild type level of laminin 15.

Methods of the invention can be used prenatally or to determine if a subject's offspring will be at risk for a disorder.

In preferred embodiments the method includes determining the structure of one or more of a laminin 15 chain gene, e.g., one or more of an $\alpha 5$ chain, the $\beta 2$ chain, or $\gamma 3$ chain gene, an abnormal structure being indicative of risk for the disorder.

In preferred embodiments the method includes contacting a sample from the subject with an antibody to one or more of the $\alpha 5$ chain, the $\beta 2$ chain, or $\gamma 3$ chain, or a nucleic acid, which hybridizes specifically with the gene.

In another aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant or unwanted expression of one or more of a laminin 15 chain or a laminin 15 activity, by administering to the subject laminin 15 or an agent which modulates expression of one or more laminin 15 chain or at least one laminin 15 activity. Subjects at risk for a disease which is caused or contributed to by aberrant or unwanted laminin 15 activity or expression of one or more laminin 15 chain can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the laminin 15 aberrance, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of laminin 15 aberrance, for example, a laminin 15 agonist or laminin 15 antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

It is possible that some laminin 15 disorders can be caused, at least in part, by an abnormal level of gene product, or by the presence of a gene product exhibiting abnormal activity. As such, the reduction in the level and/or activity of such gene products would bring about the amelioration of disorder symptoms.

The term "effective amount" means the amount that is sufficient to reduce or alleviate at least one adverse effect or symptom of a disorder and/or to induce or enhance at least one biological activity of laminin 15. A biological activity of laminin 15 includes one or more of the ability to: 1) modulate retinal development, e.g., in the subretinal space, the interphotoreceptor matrix, the outer plexiform layer; 2) modulate, e.g., promote, neural cell growth and regeneration, e.g., axonal outgrowth; 3) modulate, e.g., promote, adhesion between cells and/or extracellular matrix, e.g., retinal contact; 4) modulate, e.g., promote,

synaptic formation; 5) modulate, e.g., promote, viability of a neural cell, e.g., a neural retinal cell, e.g., a photoreceptor or an element thereof, e.g., outer segment, inner segment, cell body or synapses; 6) interact, e.g., form a complex, with a dystrophin and/or a P-dystroglycan. An effective amount can be determined by one skilled in the art, e.g., based on the disease stage, age, sex, and weight of the to be treated subject and the condition of the treatment. As a reference, the amount administered can be at a concentration of at least from about 0.1 to 500 pg/ml, from about 1 to 200 g/ml, from about 10 to 150 g/ml, or from about 10 to 100 g/ml.

The term "isolated or purified nucleic acid molecule" includes nucleic acid molecules which are separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. For example, with regards to genomic DNA, the term "isolated" includes nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and/or 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of 5' and/or 3' nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

As used herein, the term "hybridizes under stringent conditions" describes conditions for hybridization and washing. Stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N. Y. (1989), 6.3.1-6.3.6. Aqueous and nonaqueous methods are described in that reference and either can be used. A preferred, example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50°C. Another example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 55°C. A further example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C. Preferably, stringent

hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1%SDS at 65°C. Particularly preferred stringency conditions (and the conditions that should be used if the practitioner is uncertain about what conditions should be applied to determine if a molecule is within a hybridization limitation of the invention) are 0.5M Sodium Phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO: 1,3, 5, 7, or 9, or corresponds to a naturally-occurring nucleic acid molecule.

As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

An "isolated" or "purified" polypeptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. In one embodiment, the language "substantially free" means preparation of laminin 15 having less than about 30%, 20%, 10% and more preferably 5% (by dry weight), of non-laminin 15 protein (also referred to herein as a "contaminating protein"), or of chemical precursors or non-laminin 15 chemicals. When the protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The invention includes isolated or purified preparations of at least 0.01, 0.1, 1 .0, and 10 milligrams in dry weight.

A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of a laminin 15 chain (e.g., the sequence of SEQ ID NO: 1, 3, 5, 7, or 9) without abolishing or more preferably, without substantially altering a biological activity, whereas an "essential" amino acid residue results in such a change. For example, amino acid residues that are conserved among the polypeptides of the present invention, e.g., those present which mediate assembly and are predicted to be particularly unamenable to alteration.

A "conservative amino acid substitution" is one in which the amino acid residue is

replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), betabranched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a laminin 15 chain coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for a laminin 15 biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO: 1, 3, 5, 7, or 9, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.

To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least and even 60%, more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) *J Mol Biol* (48): 444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna. CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used if the practitioner is uncertain about what parameters should be applied to determine if a molecule is within a sequence identity or homology limitation of the invention) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4: 11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

"Misexpression or aberrant expression", as used herein, refers to a non-wild type pattern of gene expression, at the RNA or protein level. It includes: expression at nonwild type levels, i.e., over or under expression; a pattern of expression that differs from wild type in terms of the time or stage at which the gene is expressed, e.g., increased or decreased expression (as compared with wild type) at a predetermined developmental period or stage; a pattern of expression that differs from wild type in terms of decreased expression (as compared with wild type) in a predetermined cell type or tissue type; a pattern of expression that differs from wild type in terms of the splicing size, amino acid sequence, post-translational modification, or biological activity of the expressed polypeptide; a pattern of expression that differs from wild type in terms of the effect of an environmental stimulus or extracellular stimulus on expression of the gene, e.g., a pattern of increased or decreased expression (as compared with wild type) in the presence of an increase or decrease in the strength of the stimulus.

A "purified preparation of cells", as used herein, refers to, in the case of plant or

animal cells, an in vitro preparation of cells and not an entire intact plant or animal. In the case of cultured cells or microbial cells, it consists of a preparation of at least 10% and more preferably 50% of the subject cells.

The term "subject" as used herein refers to a mammal. Examples of mammals include human and nonhuman primates, e.g., a monkey, a goat, or a rodent, e.g., a rat or a mouse, having a disorder associated with insufficient laminin, e.g., laminin 15 activity. The mammal is preferably a primate, e.g., a human.

As used herein the term "administering" refers to delivery of a preparation, composition, an active portion, or an active fragment of laminin 15 alone, in combination with another laminin (e.g., laminin 5, laminin 14) and/or at least one other compound or preparation.

The term "stability" means structural, anatomic molecular, and/or functional integrity, intactness, or completeness which is testable or observable by any suitable means. For example, the stability of retina photoreceptor can be tested by ERG, e.g., indicated by a wave and b wave.

The term "pharmaceutically acceptable carrier" is intended to include a solvent, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Such carriers include, but are not limited to, large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Pharmaceutically acceptable salts can also be used in the composition, for example, mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates, as well as the salts of organic acids such as acetates, propionates, malonates, or benzoates. The composition can also contain liquids, such as water, saline, glycerol, and ethanol, as well as substances such as wetting agents, emulsifying agents, or pH buffering agents.

Liposomes, such as those described in U.S. 5,422,120; WO 95/13796; WO 91/14445; or EP 524,968 B1, can also be used as a carrier. Typically, the therapeutic laminin composition is prepared as an injectable, either as a liquid solution or suspension; however, solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. The composition can also be formulated into an entericcoated tablet or gel

capsule according to known methods in the art, such as those described in U. S. 4,853,230; EP 225,189; AU 9,224,296; and AU 9,230,801.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Brief Description of the Figures

Fig. 1A-1F depicts the nucleotide sequence of murine $\alpha 5$ (SEQ ID NO: 1) and the amino acid sequence of murine $\alpha 5$ (SEQ ID NO: 2).

Fig. 2A-2B depicts the nucleotide sequence of human $\alpha 5$ (SEQ ID NO: 3) and the amino acid sequence of human $\alpha 5$ (SEQ ID NO: 4).

Fig. 3A-3D depicts the nucleotide sequence of murine $\beta 2$ (SEQ ID NO: 5) and the amino acid sequence of murine $\beta 2$ (SEQ ID NO: 6).

Fig. 4A-4C depicts the nucleotide sequence of human $\beta 2$ (SEQ ID NO: 7) and the amino acid sequence of human $\beta 2$ (SEQ ID NO: 8).

Fig. 5A-5B depicts the nucleotide sequence of murine $\gamma 3$ (SEQ ID NO: 9) and the amino acid sequence of murine $\gamma 3$ (SEQ ID NO: 10).

Detailed Description

The invention features a novel member of the laminin family, i.e., laminin 15, and methods of making and using this novel laminin, e.g., in neural associated disorders.

In the methods of treating a disorder, such as a disorder described herein, laminin 15 can be administered alone, or in combination with at least one other laminin (e.g., laminin 5 and/or laminin 14) and/or with at least one other compound or preparation. Administration can include local or systemic administration, including injection, oral administration, particle gun, or catheterized administration, and topical administration. Various methods can be used to administer a therapeutic composition of laminin 15 alone, or in combination with one

another laminin, and/or compound, directly to a specific site in the body. For example, a small neural wound can be located and the therapeutic composition can be applied, e.g., once or several times in one or several different locations, within the wound. A therapeutic laminin 15 composition can be directly administered to the surface of a neural wound, for example, by topical application of the composition, or can be injected into the site of a neural wound, e.g., as part of a liquid solution or suspension. X-ray imaging can be used to assist in delivery of laminin 15 to a site, e.g., the site of a neural wound. Combination therapeutic agents, including a laminin 15 protein, a laminin 15 polypeptide, or a subgenomic laminin 15 polynucleotide, and other therapeutic agents, can be administered simultaneously or sequentially. The administration of therapeutic agents can be repeated.

Receptor-mediated targeted delivery of therapeutic compositions containing laminin 15 subgenomic polynucleotides to specific tissues can also be used. Receptor mediated DNA delivery techniques are described in, for example, Findeis et al., 1993, *Trends in Biotechnol.* 11:202-0.5; Chiou et al., 1994, GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER (J. A. Wolff, ed.); Wu & Wu., 1988, *J. Biol. Chem.* 263:621-24; Wu et al. (1994) *J Biol Chem* 269, 542-546; Zenke et al. (1990) *Proc Natl Acad Sci U.S.A.* 87:3655-59; Wu et al. (1991) *J Biol Chem* 266:338-42.

Alternatively, a laminin 15 composition can be introduced into human cells ex vivo, and the cells then replaced into the human. Cells can be removed from a variety of locations including, for example, from a selected neural tissue or from an affected organ. Both the dose of the laminin 15 composition and the means of administration can be determined based on the specific qualities of the therapeutic composition, the condition, age, and weight of the patient, the progression of the disease, and other relevant factors. If the composition contains a laminin 15 protein or polypeptide, effective dosages of the composition are in the range of about 5 pg to about 50 pg/kg of patient body weight, about 50 pg to about 5 mg/kg, about 100 pg to about 500 pg/kg of patient body weight, and about 200 to about 250 pg/kg.

Therapeutic compositions containing a laminin 15 subgenomic polynucleotide can be administered in a range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol. Concentration ranges of about 500 ng to about 50 mg, about 1 pg to about 2 mg, about 5 pg to about 500 pg, and about 20 pg to about 100 pg of DNA can also be used during a gene therapy protocol. Factors such as method of action and efficacy of transformation and expression should be considered in determining the dosage of laminin 15

polynucleotide required. Where greater expression is desired over a larger area of tissue, larger amounts of laminin 15 subgenomic polynucleotides and/or the same amounts of laminin 15 subgenomic polynucleotides can be readministered, e.g., in a successive protocol of administrations, or several administrations to different adjacent or in close proximity to the targeted tissue portions.

For example, a tumor site may be required to effect a positive therapeutic outcome. In all cases, routine experimentation in clinical trials will determine specific ranges for optimal therapeutic effect.

Isolation or recombinant production of laminin 15 ($\alpha 5$ $\beta 2$ $\gamma 3$)

Laminin 15 consists of an $\alpha 5$ chain, a $\beta 2$ chain and a $\gamma 3$ chain. The laminin chain can be isolated and purified from a natural source, e.g., from a retinal tissue such as the retina inter-photoreceptor matrix, the retina outer plexiform layer, the neural retina, a Müller cell, and/or a preparation of retinal neurons.

Alternatively, laminin 15 can be produced recombinantly or chemically synthesized by conventional methods. The nucleotide and amino acid sequences of the laminin chains are known and described, for example, at Genbank Accession Number U37501 (murine $\alpha 5$ chain), Genbank Accession Number: AW4 11963 (murine $\beta 2$ chain), and in Koch et al., *J Cell Biol* (1999) 145: 605-618 (murine $\gamma 3$ chain).

Methods of generating a recombinant laminin 15 protein are well known in the art. For example, the laminin 15 protein can be generated by cloning the nucleic acid sequence encoding each of the laminin chains into an expression vector, where it is operably linked to one or more expression control sequences.

A vector can include one or more of an $\alpha 5$ chain, the $\beta 2$ chain, and $\gamma 3$ chain nucleic acid in a form suitable for expression of the nucleic acid in a host cell. Preferably the recombinant expression vector includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. The term "regulatory sequence" includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence, as well as tissue-specific regulatory and/or inducible sequences. The design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the

invention can be introduced into host cells to thereby produce proteins or polypeptides, including fusion proteins or polypeptides, encoded by nucleic acids as described herein (e.g., laminin 15 proteins, mutant forms of laminin 15 proteins, fusion proteins, and the like).

The recombinant expression vectors of the invention can be designed for expression of laminin, 15 proteins in prokaryotic or eukaryotic cells. For example, polypeptides of the invention can be expressed in *E. coli*, insect cells (e.g., using baculovirus expression vectors), yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

The laminin 15 expression vector can be a yeast expression vector, a vector for expression in insect cells, e.g., a baculovirus expression vector or a vector suitable for expression in mammalian cells.

When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. Regulatory sequences (e.g., viral promoters and/or enhancers) operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the constitutive, tissue specific or cell type specific expression of antisense RNA in a variety of cell types. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al., Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1 (1) 1986.

In another aspect, the invention features, a cell or purified preparation of cells which include one or more exogenously introduced laminin 15 chain nucleic acid, e.g., one or more of an $\alpha 5$ chain, the $\beta 2$ chain, and/or $\gamma 3$ chain, or which otherwise misexpress one or more laminin 15 chain. The cell preparation can consist of human or non-human cells, e.g., rodent

cells, e.g., mouse or rat cells, rabbit cells, or pig cells. In preferred embodiments, the cell or cells includes one or more of a laminin 15 chain nucleic acid, e.g., a heterologous form of a laminin 15 chain nucleic acid, e.g., a gene derived from humans (in the case of a non-human cell). The laminin 15 chain or chains can be misexpressed, e.g., overexpressed or
5 underexpressed. In other preferred embodiments, the cell or cells include one or more gene(s) which misexpress an endogenous laminin 15 chain, e.g., a gene the expression of which is disrupted, e.g., a knockout. Such cells can serve as a model for studying disorders which are related to mutated or misexpressed laminin 15 chain alleles or for use in drug screening.

10 In another aspect, the invention features, a human cell, e.g., a hematopoietic stem cell, transformed with nucleic acid which encodes a subject laminin 15 chain polypeptide.

Also provided are cells, preferably human cells, e.g., human hematopoietic or fibroblast cells, in which one or more endogenous laminin 15 chain is under the control of a regulatory sequence that does not normally control the expression of the endogenous laminin
15 15 chain gene. The expression characteristics of an endogenous gene within a cell, e.g., a cell line or microorganism, can be modified by inserting a heterologous DNA regulatory element into the genome of the cell such that the inserted regulatory element is operably linked to the endogenous laminin 15 chain gene. For example, an endogenous laminin 15 gene which is "transcriptionally silent," e.g., not normally expressed, or expressed only at
20 very low levels, may be activated by inserting a regulatory element which is capable of promoting the expression of a normally expressed gene product in that cell. Techniques such as targeted homologous recombinations, can be used to insert the heterologous DNA as described in, e.g., Chappel, US 5,272,071; WO 91/06667, published in May 16, 1991.

Implants

25 Implants described herein can be neural implants, e.g., neuromuscular stimulators; auditory prostheses, e.g., speech processors; or retinal implants. Preferred neural implants are retinal implants. Retinal implants can be, e.g., subretinal or epiretinal. Subretinal devices, e.g., MPDAs, are less than 1 cm, e.g., approximately 2 millimeters, in diameter and can be composed of tiny electrodes that are powered by a large number, e.g., 3,500,
30 microscopic solar cells. Subretinal devices include the Optobionics™ silicon chip, in which light coming into the eye both powers the device and is transmitted to the brain as an image

by the device. Epiretinal devices can go on top of a damaged retina. A retinal implant can also be a biocompatible device or material designed to carry or deliver a compound or composition to the retina, e.g., an implantable tip, catheter, or tissue; or an electronic device that replaces photoreceptor function, e.g., a phototransistor.

Such implants can be contacted, e.g., coated, with the compositions described herein, e.g., for use in a subject.

Transgenic Animals

The invention provides non-human transgenic animals. Such animals are useful for studying the function and/or activity of laminin 15 and for identifying and/or evaluating modulators of a laminin 15 activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like. A transgene is exogenous DNA or a rearrangement, e.g., a deletion of endogenous chromosomal DNA, which preferably is integrated into or occurs in the genome of the cells of a transgenic animal. A transgene can direct the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal, other transgenes, e.g., a knockout, reduce expression. Thus, a transgenic animal can be one in which one or more of an endogenous laminin 15 chain gene, e.g., one or more of a $\alpha 5$ chain, the $\beta 2$ chain, or $\gamma 3$ chain, has been altered by, e.g., by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

Examples

Example 1: Laminin Expression

Antibodies which recognize the eleven known laminin chains were used to catalog the laminin chains in adult rat and human retina. The reactivity for antibodies directed against each of these chains was assessed using immunohistochemistry (Libby et al., *Invest Ophthalmol Vis Sci* (1996) 37: 1651-1661; Libby et al., *J Comp Neural* (1997) 389: 355-367). Adult rat eyecups were embedded in O.C.T. compound (Miles, Elkhart, IN) and frozen by immersion in liquid nitrogen-cooled isopentane. Transverse, 10 μ m thick sections, were

cut with a Leica cryostat and placed onto Superfrost Plus slides (Fisher, Pittsburgh, PA). Human retina specimens were obtained as unfixed transverse sections. Slides were stored at -20°C until use. For use, slides were returned to room temperature, immersed briefly in acetone (or, interchangeably, for all but the $\alpha 5,93$, and $\gamma 2$ chains, MeOH) at -20 °C, washed in phosphate-buffered saline (PBS; 137 mM NaCl, 2.68 mM KCl, 10 mM Na₂HPO₄, 1.76 mM KH₂PO₄, pH 7.4), and then incubated in primary antibodies for two hours at room temperature or overnight at 4°C. Primary antibodies were diluted in PBS containing 2% goat serum, or 2% bovine serum albumin, or both. Sections were washed in PBS and incubated in species-appropriate, affinity purified, fluorescently-labeled secondary antibodies diluted in 2% goat serum in PBS for 1 hour at room temperature. Following washes in PBS, slides were mounted in 90% glycerol and 10% water, containing paraphenylenediamine (1 mg/ml; Sigma, St. Louis, MO) to reduce photobleaching or in Prolong (Molecular Probes, Eugene, OR). The antibodies used were: laminin 1, ccl Ply1 (Life Technologies; rabbit polyclonal); laminin cr2 chain (Life Technologies; mouse monoclonal); laminin $\alpha 3$ chain (BM-2, made in one of our laboratories (REB); mouse monoclonal); laminin $\alpha 4$ chain (Miner et al. (1997) *J Cell Biol* 137:685-701; rabbit polyclonal and R17, made in one of our laboratories (REB); rabbit polyclonal), laminin $\alpha 5$ chain (Miner et al. (1995) *J Biol. Chem.* 270: 28523-28526; rabbit polyclonal and 4C7, Engvall et al. (1986) *J Cell Biol* 103: 2457-2465; Tiger et al. (1997) *J Biol. Chem.* 272: 28590-28595); laminin $\beta 1$ chain (C21, Sanes and Chiu, *Cold Spring Harbor Symp. Quant. Biol.* (1983) 48:667-678; mouse monoclonal); laminin $\beta 2$ chain (GPI, Sanes et al., *J Cell Biol.* (1990) 111:1685-1699; guinea pig polyclonal, C4, Sanes and Chiu, (1983) *supra*; mouse monoclonal and D5, Hunter et al., *Nature* (1989) 338:229-234; mouse monoclonal); laminin $\beta 3$ chain (6F12, Rouselle et al. (1991) *J Cell Biol* 114:567-576, mouse monoclonal); laminin $\gamma 1$ chain (D18, Sanes et al. (1990) *supra*; mouse monoclonal); laminin $\gamma 2$ chain (Sugiyama et al. (1995) *Eur. J Biochem.* 228:120-128; rabbit polyclonal); laminin $\gamma 3$ chain (R16, R21, Koch et al. (1999) *J Cell Biol* 145:605-618; rabbit polyclonals); laminin 5, $\alpha 3\beta 3\gamma 2$ (4101, Rouselle et al. (1991) *supra*; Marinkovich et al., *J Biol Chem* (1992) 267:17900-17906, 8Ln5 and 9Ln5, made in one of our laboratories (REB); rabbit polyclonals). 8Ln5 and 9Ln5 were made to the same antigen as the published antiserum 4101 and have the same reactivity.

Laminin Alpha Chains

Results showed that a polyclonal antiserum which recognized the three chains of laminin 1 ($\alpha 1 \beta 1 \gamma 1$) reacted only with the vasculature in the rat and human, and not with the matrix of the neural retina itself. Laminin 1 immunoreactivity was seen on the basal side of the retinal pigmented epithelium, i.e., Bruch's membrane; and in those sections in which the inner limiting membrane was present. Laminin 1 was expressed there as well. These observations suggested that the laminin $\alpha 1$ chain, a component of laminin 1, was not associated with the matrix of either the neural retina or the IPM but was a component of the basement membranes of the retina: Bruch's membrane and the internal limiting membrane.

The laminin $\alpha 2$ chain was also present in the retinal vasculature, but was not detected as being associated with ganglion cell bodies or associated with this basement membrane. The $\alpha 2$ chain does not appear to be a component of Bruch's membrane.

In contrast, the laminin $\alpha 3$ chain was present in the interphotoreceptor matrix, prominent at the external limiting membrane and at the tips of the photoreceptor inner segments. Laminin $\alpha 3$ chain immunoreactivity was also present in the outer plexiform layer. However, in contrast to the chains of laminin 1 and the laminin $\alpha 2$ chain, which were associated with elements of the vasculature in the outer plexiform layer, the laminin $\alpha 3$ chain did not appear to be associated with the larger vessels in this region. Nevertheless, the laminin $\alpha 3$ chain did appear to be present in the outer plexiform layer. It was difficult to discern whether the laminin $\alpha 3$ chain was associated with small vessels or associated with the synaptic connections in this layer. In the human retina, weak immunoreactivity for the laminin $\alpha 3$ chain was also present surrounding cell bodies of the outer and inner nuclear layers. Finally, in human retina, the laminin $\alpha 3$ chain is diffusely associated with the inner plexiform layer.

In contrast to the laminin $\alpha 1$ -3 chains, the laminin $\alpha 4$ chain appeared to have a broad distribution in rat and human retina. Immunoreactivity for the laminin $\alpha 4$ chain was present in the IPM, as well as diffusely in both the inner and outer plexiform layers. This extensive immunoreactivity in both plexiform layers, and the lack of any association with the retinal vasculature, suggested that the laminin $\alpha 4$ chain is contained within the extracellular matrix of the plexiform layers. However, the most prominent reactivity for the laminin $\alpha 4$ chain was in what appeared to be Müller cell fibers coursing through the retina. These fibers were confirmed as Müller cell processes, based on co-localization of the laminin $\alpha 4$ chain with a Müller cell marker (vimentin). Reactivity for the laminin $\alpha 4$ chain was also present in the

ganglion cell layer which may reflect that laminin $\alpha 4$ chain associated with the endfeet of Müller cells. The presence of the laminin $\alpha 4$ chain within the Müller cell suggested that the Müller cell was a source of the laminin $\alpha 4$ chain in the neural retina, consistent with the data that confirmed the Müller cell as a source of another laminin chain, $\beta 2$ (Libby et al. (1997) *supra*).

Our initial localization studies using a polyclonal antiserum raised against the laminin $\alpha 5$ chain (Miner et al. (1995) *supra*) suggested that the laminin $\alpha 5$ chain was only a component of the true basement membranes of the retina, i.e., the internal limiting membrane, Bruch's membrane, and vascular basement membranes. However, a monoclonal antibody that specifically recognizes the laminin $\alpha 5$ chain (4C7, Engvall et al. (1986) *supra*; Tiger et al. (1997) *supra*) demonstrated that the laminin $\alpha 5$ chain is more broadly distributed within the neural retina: the laminin $\alpha 5$ chain had a distribution similar to that for the laminin $\gamma 3$ chain. Specifically, the laminin $\alpha 5$ chain was present in both rat and human interphotoreceptor matrices, as well as in the outer plexiform layer in the rat. In addition, the laminin $\alpha 5$ chain, like the laminin $\alpha 1$ and $\alpha 2$ chains, was associated with the retinal vasculature. This was particularly notable in the human. Laminin $\alpha 5$ chain immunoreactivity was present in the choroid, the hyaloid vessels, the outer plexiform layer vessels and the vasculature which extends through the retina from the hyaloid vessels to the outer plexiform layer. This expression in the vasculature was similar to the expression pattern for the laminin $\alpha 5$ chain in the brain.

Together, these data suggested that all five laminin α chains were expressed in the retina, but two--the laminin $\alpha 1$ and $\alpha 2$ chains--may be associated exclusively with the retinal vasculature. In contrast to these two laminin α chains, three chains, the laminin $\alpha 3$, $\alpha 4$ and $\alpha 5$ chains, were associated with the IPM and, potentially, associated with the neural retina at synapses in the plexiform layers. Laminins at each of these locations could be provided from the cell that spans the entire thickness of the retina, the Müller cell; the Müller cell is the likely source for at least one other laminin chain, $\beta 2$ (Libby et al. (1997) *J Comp Neural* 389:355-367).

Laminin Beta Chains

As noted above, a polyclonal serum that recognized all three chains of laminin 1, including the laminin $\beta 1$ chain, reacted only with the vasculature in rat and human retina. For

the human retina, this pattern was consistent with the previously reported expression of laminin 1 (Toti et al. (1997) *Neuromusc Disord* 7:21-25). Thus, the laminin β 1 chain was not an element of the matrix of either the IPM or the neural retina. A rat reactive antibody against the β 1 chain confirmed this observation. However, as there was little authentic laminin α 1 chain in the retina, and little authentic laminin β 1 chain in the retinal vasculature of the rat, it was likely that the polyclonal serum against laminin 1 was detecting largely the laminin γ 1 chain in the vasculature of both rat and human.

As previously reported in the rat (Libby et al. (1997) *supra*), the laminin β 2 chain was present in the interphotoreceptor matrix, and appeared to be associated with the external limiting membrane. Here, a similar distribution in the human retina was demonstrated. The laminin β 2 chain, a known component of brain vasculature, was also associated with the vessels of the retina. In the human, immunoreactivity was also present surrounding cell bodies in the inner nuclear layer, as well as in the inner limiting membrane. In both species, the laminin β 2 chain was also diffusely associated with the outer plexiform layer. A comparison of this diffuse immunoreactivity to that for laminin 1 or the laminin α 2 chain suggested that the laminin β 2 chain was not only associated with the vasculature within the outer plexiform layer. The laminin β 2 chain may also be associated with the extracellular matrix of the outer plexiform layer and localized to synapses in the central nervous system, as it is in the peripheral nervous system (Hunter et al. (1989) *Nature* 338:229-234).

Laminin β 3 chain immunoreactivity was also present in the mature rat retina, as well as the mature human retina. The β 3 chain seems largely limited to the inter-photoreceptor matrix, suggesting that laminins containing the laminin β 3 chain are components of this matrix. As laminin β 3 has a tightly restricted tissue distribution in rodent (Utani et al. (1995) *Lab Invest* 72: 300-310), and has, so far, only been demonstrated as a component of laminin 5 (α 3 β 3 γ 2), it is likely that this reflects the presence of laminin 5 in the interphotoreceptor matrix.

Together, these data suggested that, although the laminin β 1 chain was associated with the basement membrane of the retinal vasculature in both rat and human retina, only two β chains, the laminin β 2 and β 3 chains, were expressed in the matrix of the IPM. Moreover, the laminin β 2 chain was also expressed in the matrix of the outer plexiform layer.

Laminin Gamma Chains

As noted above, a polyclonal serum that recognized all three chains of laminin 1, including the laminin $\gamma 1$ chain, reacted largely with the vasculature. Consistent with this observation, an antibody directed against the laminin $\gamma 1$ chain reacted only with the vasculature in both rat and human, suggesting that the anti-laminin 1 serum was reacting with at least the $\gamma 1$ chain. In addition, in the human, the laminin $\gamma 1$ chain was present at the internal limiting membrane. This may reflect production by astrocytes, the hyaloid blood vessels, and retinal ganglion cells (Sarthy and Fu (1990) *J Cell Biol* 110: 2099-2108; compare Sarthy, *Vis. Sci.* (1993) 34: 145-152). There was also some punctate immunoreactivity for the laminin $\gamma 1$ chain within the ganglion cell layer. Importantly, there was no laminin $\gamma 1$ chain reactivity in the IPM or plexiform layers. Thus, the laminin $\gamma 1$ chain was confined to the vitread side of the retina.

In contrast to the laminin $\gamma 1$ chain, the laminin $\gamma 2$ chain was present in the interphotoreceptor matrix of rat and human retina. It was also present in the hyaloid vessels, and, to a limited extent, the intraretinal capillaries of the human. Some laminin $\gamma 2$ chain was also present in the outer plexiform layer of the rat; this immunoreactivity may reflect capillary-associated laminins. As for the laminin $\beta 3$ chain, previous reports have suggested a restricted distribution of the laminin $\gamma 2$ chain (Kalhmki et al. (1992) *J Cell Biol* 119:679-693).

The laminin $\gamma 3$ chain was the most recently isolated of the growing family of laminins (Koch et al. (1999) *supra*). The tissue distribution of this chain was quite limited. However, it was most extensively expressed in the nervous system. The results showed the presence of the laminin $\gamma 3$ chain in a portion of the human and rat central nervous system. Prominent laminin $\gamma 3$ chain immunoreactivity was present in the interphotoreceptor matrix; notably, throughout the region of photoreceptor inner segments. In addition, there was marked laminin $\gamma 3$ chain immunoreactivity associated with the external limiting membrane in the rat and surrounding cell bodies within the outer and inner nuclear layers in the human. Finally, the laminin $\gamma 3$ chain was diffusely present in the outer plexiform layer, at least in the rat. As with the laminin $\alpha 3$, $\alpha 4$, and $\beta 2$ chains, it cannot be said conclusively that the laminin $\gamma 3$ chain immunoreactivity in the outer plexiform layer was concentrated at points of synaptic contacts in the outer plexiform layer. However, the laminin $\gamma 3$ chain was not associated with the vasculature present at the vitread side of the retina, and its pattern of expression was distinct from that. For laminin chains in the vasculature, such as the $\gamma 1$ chain. Therefore, it

was probable that the laminin $\gamma 3$ chain in the outer plexiform layer was contained within the matrix of the plexiform layer.

Together, these data suggest that the laminin $\gamma 2$ and $\gamma 3$ chains were the only known laminin γ chains in the IPM. Furthermore, the laminin $\gamma 3$ chain appears to be the only laminin γ chain found potentially associated with the synaptic regions of the outer plexiform layer in both rat and human.

Thus, in the IPM, seven laminin chains: $\alpha 3$, $\alpha 4$, $\alpha 5$, $\beta 2$, $\beta 3$, $\gamma 2$ and $\gamma 3$ were present. This was consistent with the presence of one previously isolated laminin, laminin 5 ($\alpha 3\beta 3\gamma 2$), as well as several novel laminin heterotrimers. If the other chains were to combine, there would be at least two such novel laminin trimers in the IPM: $\alpha 4\beta 2\gamma 3$ and $\alpha 5\beta 2\gamma 3$. In the matrix of the outer plexiform layer, these two trimers also appear to be present, as their component chains are present. In contrast, only one laminin chain, $\alpha 4$, is prominent in the matrix of the inner plexiform layer, suggesting that other, uncharacterized, β and γ chains may be expressed in the retina.

Example 2: RNA Expression

cRNA probes which recognize the RNAs encoding the eleven known laminin chains were used to catalog these RNAs in the retina and to localize them to particular cell types using *in situ* hybridization. As laminin trimers are assembled prior to secretion, the RNAs encoding all three chains of any given trimer should be present in the same cell.

In situ hybridization was performed as follows. Adult rat eye cups were dissected and fixed overnight at 4°C in 4% paraformaldehyde in PBS (pH 7.4), dehydrated, and embedded in paraffin. Fifteen micron-thick sections were cut and placed onto Probe-on Plus slides (Fisher). Human retina specimens were obtained as fixed transverse sections. Rehydrated rat sections or frozen human sections were then processed for *in situ* hybridizations as previously described (Libby et al. (1997) *supra*).

cRNA probes for the laminin chains were generated as previously described (Libby et al. (1997) *supra*). Probes for the laminin $\beta 1$ and $\beta 2$ chains and for cellular retinaldehyde binding protein were those used previously (Libby et al. (1997) *supra*). A cRNA probe for the laminin $\alpha 5$ chain (Miner et al. (1995) *supra*) was generated. cRNAs were labeled during transcription by the incorporation of digoxigenin-UTP (Boehringer Mannheim, Indianapolis, IN); 1 μ g/ml of cRNA was used for hybridization.

Laminin Alpha Chains

5 RNAs encoding the laminin $\alpha 1$ and $\alpha 2$ chains were not readily detected in the rat or human retina, suggesting that both of these RNAs were not abundant in the retina. However, for both chains, some RNA was detected in the inner nuclear layer. This may reflect production of these two chains by components of the vasculature.

10 In contrast, the RNA encoding the laminin $\alpha 3$ chain was readily detectable in the rat and human retina. This expression agrees with the high expression levels of the laminin $\alpha 3$ chain in the retina from the human expressed sequence tag database. Interestingly, laminin $\alpha 3$ chain RNA was not localized to perinuclear sites. Rather, the RNA was in fibers coursing through the inner and outer nuclear layers and the outer plexiform layer. This location was consistent with production of laminin $\alpha 3$ chain RNA by Müller cells.

15 The RNA encoding the laminin $\alpha 4$ chain was present in a pattern similar to that encoding the laminin $\alpha 3$ chain. The RNA appeared to be located in fibers coursing through the inner and outer nuclear layers, which were likely to be Müller cell processes. Unlike laminin $\alpha 3$ chain RNA, there did seem to be perinuclear laminin $\alpha 4$ chain RNA in the inner nuclear layer, particularly of the human retina, suggesting that the source of the RNA encoding the laminin $\alpha 4$ chain was a cell whose nucleus resides in the inner nuclear layer. Müller cell nuclei were in this layer. Finally, in human retina, laminin $\alpha 4$ chain RNA was present in the ganglion cell layer, in what was presumed to be Müller cell endfeet.

20 Similar to the laminin $\alpha 1$ and $\alpha 2$ chain, RNA encoding the laminin $\alpha 5$ chain was not detectable within the rat retina. This suggests that the RNA encoding the laminin $\alpha 5$ chain was not abundant in the rat retina. In an example of species variation, RNA encoding the laminin $\alpha 5$ chain within the human neural retina of the human was detected. The pattern of expression for laminin $\alpha 5$ chain RNA in the human retina was similar to, albeit considerably less intense than, that detected with a probe for laminin $\alpha 4$ chain RNA.

25 Together, the patterns of expression for the RNAs encoding the laminin α chains suggest that the laminin $\alpha 3$, $\alpha 4$ and $\alpha 5$ chain RNAs were expressed in the neural retina, consistent with the presence of laminin $\alpha 3$, $\alpha 4$ and $\alpha 5$ chain protein noted above. Specifically, they suggested that laminin $\alpha 3$, $\alpha 4$ and $\alpha 5$ chains were produced in the neural retina and deposited in the matrices of the IPM and outer plexiform layer, and, in the case of the laminin $\alpha 4$ chain, the inner plexiform layer.

Laminin Beta Chains

RNA encoding the laminin $\beta 1$ chain was not highly expressed in the neural retina, as previously reported (Libby et al. (1997) *supra*). These data were consistent with the lack of laminin $\beta 1$ chain protein in neural structures within the retina.

5 It was previously shown that the laminin $\beta 2$ chain was expressed in the adult rat retina (Libby et al. (1997) *supra*). RNA encoding the laminin $\beta 2$ chain was present in fibers in the outer and inner nuclear layers of the rat. In the human retina, RNA encoding the laminin $\beta 2$ chain was present in what appear to be fibers in the inner and outer nuclear layers. It was striking at the external limiting membrane, and was also present in the ganglion cell
10 layer. It had been previously ascribed that the laminin $\beta 2$ chain RNA was in the ganglion cell layer to Müller cell endfeet (Libby et al. (1997)). There was also perinuclear RNA present in and around some cell bodies in the inner nuclear layer, suggesting a cell in the inner nuclear layer, possibly the Müller cell, was a source of the laminin $\beta 2$ chain in the neural retina. Finally, as shown here, for the rat, and here for the human, this pattern of RNA
15 expression was similar to that for cellular retinaldehyde binding protein, an authentic marker of the Müller cell (Bunt-Milam and Saari (1983) *J Cell Biol* 97:703-712).

Laminin $\beta 3$ chain RNA appears to be expressed in the adult rat retina. RNA encoding the laminin $\beta 3$ chain was located in fibers coursing through the inner and outer nuclear layers, in the outer plexiform layer, and at the outer limiting membrane. In another
20 example of species variation, laminin $\beta 3$ chain RNA could not be detected within the human neural retina.

Together, these data suggested that, in both rat and human, the laminin $\beta 2$ chain was the prominent β chain expressed in the neural retina. In addition, the laminin $\beta 3$ chain appeared to be a component of the neural retina. Finally, the laminin $\beta 1$ chain was not likely
25 to be expressed in the mature neural retina.

Laminin Gamma Chains

The RNA encoding the laminin $\gamma 1$ chain could not be detected in the neural retina. This suggested that the laminin $\gamma 1$ chain protein in the internal limiting membrane was not derived from the neural retina. The laminin $\gamma 1$ chain in the internal limiting membrane must,
30 therefore, be derived from one of the non-neural retinal cells that contact it. Both astrocytes and the hyaloid vessels contact the internal limiting membrane and have been suggested as

sources for protein components of the internal limiting membrane (Sarthy and Fu (1990) *supra*; Sarthy (1993) *supra*).

RNA encoding the laminin $\gamma 2$ chain was consistently difficult to detect in the retina. However, the RNA was detectable in the inner nuclear layer of the human retina, and to a lesser extent, the rat retina.

In contrast, RNA encoding the laminin $\gamma 3$ chain was readily detected in both the rat and human retina. Laminin $\gamma 3$ chain RNA was expressed in a pattern that is similar to that for several other laminin chain RNAs. In fibers coursing through the outer nuclear layer, at the external limiting membrane, and in presumed Müller cell endfeet in the ganglion cell layer. The $\gamma 3$ chain was, therefore, a likely γ component of mature retinal laminin.

Thus, the expression patterns for the laminin chain RNAs detected in the neural retina demonstrated that RNAs encoding the laminin $\alpha 3$, $\alpha 4$, $\beta 2$, $\gamma 2$ and $\gamma 3$ chains are expressed in the rat and human retina; in addition, RNA encoding the laminin $\alpha 5$ chain was detected in human retina, and that encoding the laminin $\beta 3$ chain was detected in rat retina. Although slightly different, the basic distribution of all of these RNAs was the same: largely within fibers coursing through the inner and outer nuclear layers. RNAs for the laminin $\alpha 4$ and $\beta 2$ chains also appear to be present at perinuclear sites in the inner nuclear layer as well as within the ganglion cell layer. Together, these data suggested that the Müller cell is the source of these laminin chain-encoding RNAs. In addition, it supports that the retina produces two novel laminin trimers: laminin 14 ($\alpha 4\beta 2\gamma 3$) and laminin 15 ($\alpha 5\beta 2\gamma 3$).

Example 3: Biochemical Identification of Laminin 14 and 15 in the Retina

The protein and RNA localization data suggested that laminins 5, 14 and 15 were expressed in the neural retina. These findings were extended by isolating laminins, and their component chains, from the retina.

The biochemical isolation of laminin heterotrimers was preformed as follows. Bovine eyes were obtained from Pel-Freez (Rogers, AR) and dissected to isolate the retina. About 50 retina were pooled, washed in PBS containing the protease inhibitors phenylmethylsulfonyl fluoride (150 mg/l) and N-ethylmaleimide (650 mg/l), frozen in liquid nitrogen, ground in a Waring blender and resuspended in 100 ml of 2 M urea, 0.5M NaCl, 10mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 5 mM N-ethylmaleimide, and 50mM Tris-HCl (pH 7.8), then stirred for 24 hours at 4°C. The retinal extract was cleared by

centrifugation at 30,000 g for 60 min, dialyzed in 0.5M NaCl and 50mM Tris-HCl (PH 7.8), then cleared by centrifugation at 100,000 g for 60 min. Glycoproteins were isolated by applying the extract to a Concanavalin-A-Sepharose column (Pharmacia, Piscataway, NJ). Unbound material was removed by washing with 0.5M NaCl, 5m. M CaCl₂, 5 mM MgCl₂ and 50mM Tris-HCl (pH 7.4). The column was washed with 10mM α -D-methylmannopyranoside in 0.5 M NaCl and 50 mM Tris-HCl (PH 7.4) and then eluted with 1 M α -D-methylglucopyranoside in 0.5 M NaCl and 50 mM Tris-HCl pH 7.4).

To isolate laminin 14 and laminin 15, the Concanavalin-A eluate was separated without sulfhydryl reduction on a 3-5% polyacrylamide-SDS gel. After staining with Coomassie Brilliant Blue R-250 (Sigma), bands containing the high molecular weight proteins were excised, washed in 0.5 M Tris-HCl pH 6.8), incubated in SDS sample buffer containing 10% P-mercaptoethanol for 30 minutes at ambient temperature, and the different laminin chains were separated on a 5% polyacrylamide-SDS gel. Proteins were analyzed by protein transfer ("Western") blot analysis using an anti-laminin α 4 chain antiserum (R17), an anti-laminin β 2 chain antibody (D5) , and an anti-laminin γ 3 chain antiserum (R21).

The 380 kD protein isolated by this method was not reactive with any of the anti-laminin antibodies. Therefore, following digestion by the protease Lys-C, peptide fragments of this protein were sequenced using matrix-assisted laser desorption time-of-flight mass spectrometry (Chait and Kent (1992) *Science* 257:1885-1 894) performed on a Finnegan Lasermat 2000.

Although the presence of the laminin α 3 chain protein on protein transfer blots of retinal extracts was demonstrated, it has been impossible to isolate any heterotrimeric laminins containing the laminin α 3 chain from retinal extracts, and have, therefore, been unable to confirm biochemically the presence of laminins 5 (α 3 β 3 γ 2) or 13 (α 3 β 2 γ 3). This may reflect a relative dearth of these trimers in the retina, or a difficulty in extracting them in a native form. However, it has been previously shown that the laminin β 2 chain is present in retinal extracts (Hunter et al. (1992) *Neuron* 8:399-413). In addition, laminins eluted from an anti-laminin β 2 chain resin contain the α 4 chain, demonstrating that the β 2 chain is associated with at least this chain in the retina.

Retinal laminins were isolated from retinal matrix by chromatography on Concanavalin A-Sepharose followed by size fractionation on polyacrylamide gels. Two high-molecular weight components were selected from this purification scheme. Each was

reduced and separated on polyacrylamide gels. The first (band "A") resolved into components of approximately 190, 220, and 380 kD. Two of these proteins were identified immunologically as the laminin β 2 (190 kD) and γ 3 (220 kD) chains. The third did not react with any of the anti-laminin antibodies (e.g., anti- α 4). The second high molecular weight component (band "B") resolved into components of approximately 190 and 220 kD. The 190 kD component consisted of both the α 4 and β 2 chains, and the 220 kD component was identified as the γ 3 chain. No other chains were detected as components of this complex; therefore, band "B" consists of the novel laminin composed of α 4, β 2, and γ 3 chains, which was term laminin 14.

The high molecular weight of this protein suggested that band "A", was a laminin α chain, perhaps the laminin α 5 chain. However, as antibodies did not react with this protein, it was excised from a polyacrylamide gel, digested, and microsequenced. The resultant fragments were compared to known laminin sequences, and all were identical to sequences within the laminin α 5 chain (Table One), demonstrating that this third component is the laminin α 5 chain. Therefore, band "B" consists of the novel laminin composed of α 5, β 2, and γ 3 chains, which was term laminin 15.

Table One

peptide 1	AHPVSNAIDGTER
mouse laminin α 5 (36-48)	AHPVSNAIDGTER
peptide 2	WWQSPPLSR
mouse laminin α 5 (53-61)	WWQSPPLSR
peptide 3	FANSRPDLWVLER
mouse laminin α 5 (83-96)	FANSRPDLWVLER
peptide 4	TNTLLGHLMGK
mouse laminin α 5 (188-198)	TNTLLGHLMGK
peptide 5	FGFNPLEFENFSWR
mouse laminin α 5 (797-810)	FGFNPLEFENFSWR
peptide 6	LELEEAATPEGHAVR
mouse laminin α 5 (813-827)	LELEEAATPEGHAVR
peptide 7	AGALLPAIR
mouse laminin α 5 (2099-2107)	AGALLPAIR

peptide 8
mouse laminin $\alpha 5$ (2640-2646) KLIAQAR
KLIAQAR

Expression of Laminins 5, 14, and 15 During Retinal Development

5 It was previously shown that the laminin $\beta 2$ chain was expressed throughout retinal development (Libby et al. (1996) *supra*; Libby et al. (1997) *supra*), at first in the subretinal space, and subsequently in the interphotoreceptor matrix and the outer plexiform layer. In addition, it was recently shown that the laminin $\beta 2$ chain is critical for proper formation and function of synapses in the outer plexiform layer (Libby et al. (1999) *J Neurosci.* 19: 9399-10 9411). These observations were extended by examining the expression of potential partners for the laminin $\beta 2$ chain, i.e., components of laminins 14 and 15, during development of the interphotoreceptor matrix and outer plexiform layer. In the course of these experiments, it was also found that the components of laminin 5 ($\alpha 3 \beta 3 \gamma 2$) were expressed in the developing retina. The expression of the components of laminins 14 and 15 were examined, as well as 15 those of laminin 5 (the laminin $\alpha 3$, $\alpha 4$, $\alpha 5$, $\beta 2$, $\beta 3$, $\gamma 2$, and $\gamma 3$ chains) from postnatal day 0 (P0) through postnatal day 15 (P15). The appearance of these chains was compared with that for two components of the photoreceptor synapse, dystrophins and pdystroglycan.

At P0, few rod photoreceptors have differentiated in the rat retina, and the outer plexiform layer had not yet formed (and, therefore, no dystrophins are present). At this age, 20 the laminin $\beta 2$ chain is prominently expressed in the subretinal space, as previously reported at E2 1 (Libby et al., 1996, *supra*), and in fibers spanning the width of the retina, as are the other components of laminins 14 and 15, the laminin $\alpha 4$, $\alpha 5$, and $\gamma 3$ chains. In addition, the laminin $\alpha 3$, $\beta 3$, and $\gamma 2$ chains are also expressed in these locations, and an antiserum against laminin 5 displays similar immunoreactivity. These immunohistochemical data are 25 consistent with the expression of laminins 14 ($\alpha 4 \beta 2 \gamma 3$), 15 ($\alpha 5 \beta 2 \gamma 3$), and 5 ($\alpha 3 \beta 3 \gamma 2$) at P0. However, none of the laminin chains were concentrated in the region that will eventually become the outer plexiform layer.

At P5, the central portion of the retina had begun to elaborate an outer plexiform layer, in which dystrophins were expressed, whereas the peripheral portion had not. At this 30 age, the components of laminins 14 and 15 were still present in the subretinal space and in fibers spanning the thickness of the retina. In addition, in the central portion of the retina, these laminin chains were beginning to be concentrated in the developing outer plexiform

layer. Components of laminin 5 remained associated with the subretinal space and in fibers spanning the thickness of the retina. At P10, the entire retina had developed an outer plexiform layer, in which dystrophins were prominently expressed. Interestingly, another component of the adult photoreceptor synapse, β -dystroglycan, was not detectable at this age. The components of laminins 14 and 15 (the $\alpha 4$, $\alpha 5$, $\beta 2$, and $\gamma 3$ chains) were concentrated in the developing interphotoreceptor matrix and the outer plexiform layer. In addition, laminin 5 immunoreactivity remained associated with the subretinal space and the outer plexiform layer. In addition, monoclonal antibodies against all three chains of laminin 5 ($\alpha 3$, $\beta 3$ and $\gamma 2$) were reactive, suggesting that laminin 5 expression continues.

At P15, the outer plexiform layer was beginning to reach maturity, as judged by the continued presence of dystrophins and now detectable levels of β -dystroglycan. In other respects, the retina at P15 is similar to the adult: the components of laminins 14 and 15, including the laminin $\alpha 4$, $\beta 2$, and $\gamma 3$ chains are prominently expressed in the interphotoreceptor matrix and outer plexiform layer, the $\alpha 4$ chain is prominent in fibers spanning the retina, and laminin 5 remains. Expression of one component of the outer plexiform layer, β -dystroglycan, appeared to lag behind the others. By $\beta 26$, however, the expression closely mimics that of the adult.

In summary, the developing retina contained components of laminins 14 and 15 throughout the period of inter-photoreceptor matrix and outer plexiform layer formation. Initially, these chains were expressed in the subretinal space and in fibers spanning the thickness of the retina. With time, they became more restricted to, the interphotoreceptor matrix and outer plexiform layer, reflecting the distribution present in the adult. In addition, components of laminin 5 are expressed in the interphotoreceptor matrix and outer plexiform layer of the developing retina, but become somewhat restricted to the interphotoreceptor matrix by the time a mature morphology is attained. Remarkably, one component of the putative laminin-binding dystrophin complex, β -dystroglycan, is expressed relatively late in retinal synaptogenesis, well after the dystrophins and laminins.

Laminins in the immunophotoreceptor Matrix (IPM) and retinal synaptic layers

The immunohistochemical studies reported herein, on rat and human retina, show laminin chains $\alpha 3$, $\alpha 4$, $\alpha 5$, $\beta 3$, $\gamma 2$, and $\gamma 3$ surround inner segments, which are likely to reflect a location in the IPM. In the IPM, laminins may be important in maintaining the proper

5 mature environment for photoreceptors. The proposed role for laminins in the IPM, given that laminins are known to be involved in adhesion and that the IPM is thought to be important in retinal adhesion is in retinal adhesion. This is particularly likely for laminin 5, previously shown to be critical for dermal adhesion. It is described herein that photoreceptors can adhere to recombinant laminin $\beta 2$ chain. It will now be possible to determine whether the heterotrimeric laminins in the IPM are involved in photoreceptor adhesion. Several laminin chains are also present in the mature plexiform layers. In particular, the laminin $\alpha 3$, $\alpha 4$, $\alpha 5$, $\beta 2$, and $\gamma 3$ chains were expressed in the outer plexiform layer in a location not likely to be associated with the vasculature.

10 Müller cells produce retinal laminins

The RNA encoding the laminin chains that are expressed in the mature neural retina are located in cells that span the retina. This location was consistent with the production of laminins by Müller cells. Müller cell cytoplasm is spread across the retina (Rasmussen (1972) *J Ultrastruct Res* 39:413-429) and RNA is distributed throughout these processes. In addition, it was shown that the distribution of RNA encoding CRALBP, in both rat and human retina (Libby et al. (1997) *supra*), is similar to that of the laminins: throughout the retina, in fibers coursing through the retinal cell layers. Together with the immunohistochemical data noted above, these data support a Müller cell source for laminins in the IPM and synaptic layers.

20 Laminins in the nervous system

In the peripheral nervous system, several cell types produce a variety of laminins. For example, the glial elements that wrap peripheral nerves, Schwann cells, have long been known to produce laminins, including at least one that contains the $\beta 2$ chain. Conversely, laminins are thought to be important during Schwann cell differentiation. Also in the periphery, muscle cells appear to express several different laminin trimers on their surface, which are likely to be important in guiding innervating motor neurons to their synaptic targets in the muscle, as well as for stabilization of the synapse (Hunter et al. (1989) *Nature* 338:229-234). Importantly, one laminin chain, $\alpha 2$, has been shown to be involved in muscular dystrophies: mutations in $\alpha 2$ have been found in murine muscular dystrophies (Xu et al., (1994) *Nut Genet* 8:297-302; Sunada et al. (1995) *Hum Mol Genet* 4:1055-1061) and in some cases of a human congenital muscular dystrophy (Helbling-Leclerc et al. (1995) *Nut*

Genet 11:216-218).

Similarly, in the central nervous system, laminins are present in a variety of areas, particularly during development. The cellular sources of their component chains include all three major cell classes of the central nervous system: glia, neurons, and neuroglial progenitors. Glial cells, including astrocytes, Bergmann glia, and Müller cells, are thought to be a major source of laminins in the adult and developing CNS (Libby et al. (1997) *supra*). Neurons may also produce laminins (Sarthy and Fu (1990) *J Cell Biol* 110: 2099-2108). Finally, it has been shown that the retinal neuroglial progenitor may be a source of laminins during development (Libby et al. (1997) *supra*).

The ability of all of the major neural cell types of the CNS to produce laminins is consistent with the profusion of roles that have been proposed for laminins in the CNS. Most notably, as with laminins in the peripheral nervous system, laminins in the CNS are thought to be involved with axon outgrowth, based upon the laminins known roles in axon outgrowth in vitro (reviewed in Sanes (1989) *Ann Rev Neurosci* 12:491-516; Liesi (1990) *Experientia* 46:900-907) and their distribution along many developing pathways (see, for example, Cohen et al. (1987) *Dev Biol* 22: 407-418; and Liesi and Silver (1988) *Dev Biol* 130:774-785; Zhou (1990) *Dev Brain Res* 55:191-201). Laminins are also thought to be involved with neuronal differentiation in the CNS. For example, it has been shown that retinal laminins containing the $\beta 2$ chain can promote rod photoreceptor differentiation in vitro (Hunter and Brunken (1997) *Mol Cell Neurosci* 10:7-15). In addition, it has been shown that $\beta 2$ chain-containing laminins are vital during the differentiation of photoreceptors and their synapses in vivo (Libby et al. (1999) *supra*).

Novel laminin trimers in the central nervous system

Retinal basement membranes contain the laminin $\alpha 1$, $\alpha 5$, $\beta 1$, $\beta 2$, and $\gamma 1$ chains. In contrast, the neural retina has a different complement of at least seven laminin chains: $\alpha 3$, $\alpha 4$, $\alpha 5$, $\beta 2$, $\beta 3$, $\gamma 2$ and $\gamma 3$. Of these, it is probable that the $\alpha 3$, $\beta 3$, and $\gamma 2$ chains assemble to form laminin 5, although laminin 5 has not been purified from retinal extracts. However, together with the biochemical data, the expression data suggest that there are at least two novel laminin trimers, laminin 14 ($\alpha 4 \beta 2 \gamma 3$) and laminin 15 ($\alpha 5 \beta 2 \gamma 3$), in the CNS. The apparent loss of the $\beta 3$ chain in the adult outer plexiform layer suggests that there could be an additional novel laminin present, laminin 13 ($\alpha 3 \beta 2 \gamma 3$).

Intriguingly, laminins 14 and 15 appear to be expressed in two locations: (1) within the inter-photoreceptor matrix, and (2) in the outer plexiform layer. The location of these laminins in the outer plexiform layer suggests that they may serve to stabilize retinal synapses, in a manner analogous to that suggested for β 2-containing laminins, perhaps including laminin 11, at the neuromuscular junction. Laminins 14 and 15 are the first laminins that could be involved in formation or stabilization of synapses within the CNS. Moreover, these laminins are present at the same location as two components of the dystrophin complex--dystrophins and β -dystroglycan. The ability to examine the presence of all known laminin chains has allowed the demonstration that laminins are, in fact, associated with dystrophin complexes at central synapses, just as they are at the neuromuscular junction. However, as laminin expression precedes that of one component of the dystrophin complex (β -dystroglycan), it seems likely that it is not necessary to assemble the entire complex in order to stabilize laminins at the photoreceptor synapse.

The data describing the presence of laminin 5 during development suggests that this trimer may also be involved in retinal differentiation. This data, along with the data that suggest the presence of laminins 14 and 15 during development, provide support that laminins are critical components of the extracellular environment during differentiation of the nervous system. Laminins are also ubiquitously expressed in the vertebrate nervous system. All patents and references cited herein are incorporated in their entirety by reference. Other embodiments are within the following claims.

What is claimed:

1. A substantially pure preparation, comprising: a laminin wherein the laminin comprises laminin chain $\alpha 5$, laminin chain $\beta 2$, and laminin chain $\gamma 3$.
2. The preparation of claim 1, wherein the laminin is laminin-15.
- 5 3. A cell which comprises a nucleic acid encoding a laminin $\alpha 5$ chain, a nucleic acid encoding a laminin $\beta 2$ chain, and a nucleic acid encoding a $\gamma 3$ chain, wherein the cell is capable of producing laminin-15.
4. A composition comprising the protein preparation of claim 1 and a pharmaceutically acceptable carrier.
- 10 5. A method of isolating the preparation of claim 1, comprising:
obtaining a retinal tissue selected from the group consisting of retina
interphotoreceptor matrix, retina outer plexiform layer, neural retina, Müller cell, a
preparation of retinal neurons; and
isolating the preparation of claim 1.
- 15 6. A method of increasing retina immunophotoreceptor matrix stability, comprising:
administering an effective amount of the preparation of claim 1.
7. A method of increasing the stability of one or more retina photoreceptor
components, comprising: administering an effective amount of the preparation of claim 1.
- 20 8. The method of claim 7, wherein the retina photoreceptor component is an outer
segment, inner segment, cell body, or synapse.
9. A method of increasing retina adhesion, comprising: administering an effective
amount of the preparation of claim 1.

10. A method of treating a disorder associated with retina degeneration, comprising:
administering an effective amount of the preparation of claim 1.

11. The method of claim 10, wherein the disorder is selected from a group consisting
of: rod dystrophy, rod-cone dystrophy, retinitis pigmentosa, macular degeneration, and
5 retinal detachment.

12. A method of increasing the stability of synapses, comprising: administering an
effective amount of the preparation of claim 1.

13. The method of claim 12, wherein the synapses are selected from the group
consisting of synapses of central nervous system and synapses of peripheral nervous system.

10 14. A method of stimulating a condition, comprising: administering an effective
amount of a compound comprising the preparation of claim 1, wherein the condition is
neuroregeneration, axon outgrowth, or formation of synapses.

15. The method of claim 14, wherein the synapses are selected from the group
consisting of: synapses of central nervous system and synapses of peripheral nervous system.

15 16. A method of preparing an implant, comprising: coating the implant with the
preparation of claim 1.

17. The method of claim 16, wherein the implant is selected from the group
consisting of: an implantable tip, an implantable catheter, an artificial joint, a retinal implant,
a timed releasing device, a neural cell growth guide, and an artificial tissue.

20 18. A method of increasing photosensitivity, comprising: implanting a tip coated with
an effective amount of the preparation of claim 1 into an eye.

19. The preparation of claim 1, wherein the laminin is recombinant.

20. A method for producing laminin 15, comprising: expressing laminin chain $\alpha 5$, laminin chain $\beta 2$, and laminin chain $\gamma 3$, and producing laminin 15.

21. The method of claim 20, wherein the laminin chain $\alpha 5$, laminin chain $\beta 2$, and laminin chain $\gamma 3$ are co-expressed in a cell.

5 22. The method of claim 21, wherein the laminin chain $\alpha 5$, laminin chain $\beta 2$, and laminin chain $\gamma 3$ are expressed in different cells.

Amino Acid Sequence and Nucleotide Sequence Encoding Murine Alpha5 Chain

DLYCKLVGGPVAGGDPNQTIQGQYCDICTAANSNKAHPVSNAIDGTERWWQSP
PLSRGLEYNEVNVTLDLGQVFHVAYVLIKFANSRPPDLWVLERSTDFGHTYQPW
QFFASSKRDCLERFGPRTLERTQDDDVICTTEYSRIVPLENGEIVVSLVNGRPGAL
NFSYSPLLRFDTKATNIRLRLRFLRTNTLLGHLMGKALRDPTVTRRYYSIKDISIGG
RCVCHGHADVCDAKDPLDPFRLQCACQHNTCGGSCDRCCPGFNQQPWKPATTD
SANECQSCNCHGHAYDCYYDPEVDRNASQNQDNVYQGGGVCLDCQHHTTGI
NCERCLPGFFRAPDQPLDSPHVCRCDCESDFTDGTCELTGRCYCRPNFTGELC
AACAEGYTDFPHCYPLPSFPHNDTREQVLPAGQIVNCDCNAAGTQGNACRKDPR
LGRCVCKPNFRGAHCELCAPGFHGPSCHPCQCSSPGVANSLCDPESGQCMCRTG
FEGDRCDHCALGYFHFPLCQLCGCSPAGTLPEGCDEAGRCQCRPGFDGPHCDRC
LPGYHGYPDCHACACDPRGALDQQCGVGGGLCHCRPGNTGATCQECSPGFYGF
SCIPCHCSADGSLHTTCDPTTGQCRCPRTVTGLHCDMCPGAYNFPYCEAGSCH
PAGLAPANPALPETQAPCMCRAHVEGPPSCDRCKPGYWGLSASNPEGCTRCSDP
RGTLLGGVTECQGNQCFCKAHVCGKTCACKDGGFFGLDYADYFGCRSCRCDV
GGALGQGCEPKTGACRCRPNTQGPTCSEPAKDHYLPDLHMMRLELEEAATPEGH
AVRFGFNPLEFENFSWRGYAHMMAIQPRIVARLNVTSPLDFRLVFRYVNRGSTS
VNGQISVREEGKLSSCTNCTEQSQPVAFPPSTEPFVTVPQRGFGEPFVLNPGIWA
LLVEAEGVLLDYVVLPLSTYYEAALLQHRVTEACTYRPSALHSTENCLVYAHLP
LDGFPSAAGTEALCRHDNSLPRPCPTEQLSPSHPLATCFGSDVDIQLEMAVPPQG
QYVLVVEYVGEDSHQEMGVAVHTPQRAPQQGVNLHPCPYSSLCRSPARDTQH
HLAIFHLDSEASIRLTAEQAHFFLHSVTLVPVEEFSTEFVEPRVFCVSSHGTFFNPSS
AACLASRFKPPQPIILKDCQVLPLPPDLPLTQSQELSPGAPPEGPQPRPPTAVDPN
AEPTLLRHPQGTVVFTTQVPTLGRYAFLHGYQPVHPSFPVEVLINGGRIWQGH
NASFCPHGYGCRTLVLCEGQTMLDVTDNELTVTVRVPEGRWLWLDYVLIVPED
AYSSSYLQEEPLDKSYDFISHCATQGYHISPSSSSPFCRNAATSLSLFYNNALPC
GCHEVGAVSPTCEPFGGQPCRGHVIGRDCSRCATGYWGFNCRPCDCGARLCD
ELTGOCICPPRTVPPDCLVCQPQSFCHPLVGCEECNCSGPGVQELTDPTCDMDS
GQCRCPNVAGRCDTCAFGFYGYPSRCPCDCHEAGTMASVCDPLTGQCHCKE
NVQGSRCQCRVGTFSLDAANPKGCTRCFCGATERCGNSNLARHEFVDMEGW
VLLSSDRQVVPHEHRPEIELLHADLRVADTFSELYWQAPPSYLGDRVSSYGGTL
HYELHSETQRGDIFIPYESRPDVVLQGNQMSIAFLELAYPPPGQVHRGQLQLVEG
NFRHLETHNPVSREELMMVLAGLEQLQIRALFSQTSSSVSLRRVVLEVASEAGRG
PPASNVELCMCPANYRGDSCQECAPGYRDTKGLFLGRCVPCQCHGHSDRCLP
GSGICVGCQHNTGDCQCRCPGFVSSDPNPASPCVSCPCPLAVPSNNFADGCV
LRNGRTQCLCRPGYAGASCERCAPGFFGNPLVLGSSCQPCDCSGNGDPNMIFSD
CDPLTGACRGLRHTTGPHCERCAPGFYGNALLPGNCTRCDCSPCGTETCDPQS
GRCLCKAGVTGQRCDRCLEGYFGFEQCQGRPCACGPAAGKSECHPQSGQCHC
QPGTTGPQCLECAPGYWGLPEKGCRRQCPRGHCDPHTGHCTCPPGLSGERC
CSQQHQVPVPGKPGGHGIHCEVCDHCVVLLDDLERAGALLPAIREQLQGINASS
AAWARLHRLNASIADLQSKLRRPPGPRYQAAQQLQTLEQQSISLQDTERLGSQ
ATGVQGGAGQLLDTTESTLGRAQKLLSVRAVGRALNELASRMGQSGPDALV
PSGEQLRWALAEVERLLWDMRTRDLGAQGAVAEAEAEQRLMARVQEQLTS
FWEENQSLATHIRDQLAQYESGLMDLREALNQAVNTTREAELNSRNQERVKE
ALQWKQELSQDNATLKATLQAASLILGHVSELLQGIDQAKEDLEHLAASLDGA

Figure 1A

WTPLLKRMQAFSPASSKVDLVEAAEAHAQKLNQLAINLSGILGINQDRFIQRAV
 EASNAYSSILQAVQAAEDAAGQALRQASRTWEMVVQRGLAAGARQLLANSSAL
 EETILGHQGRGLAQGRLOAAGIQLHNVWARKNQLAAQIQEAQAMLAMDTSET
 SEKIAHAKAVAAEALSTATHVQSOLQGMQKNVERWQSOLGGLOGQDLSQVER
 DASSSVSTLEKTLPQLLAKLSRLENRGVHNASLALSANIGRVRKLIQAARSAASK
 VKVSMKFNGRSGVRLRPPDLADLAAYTALKFHIQSPVPAPEPGKNTGDHFVLY
 MGSROATGDYMGVSLRNQKVHWVYRLGKAGPTTLSIDENIGEQAASVSDRTL
 QFGHMSVTVEKQMVHEIKGDTVAPGSEGLLNHPDDFVFYVGGYPSNFTPPEPL
 RFPGYLGCIEMETLNEEVVSLYNFEQTFMLDTAVDKPCARSKATGDPWLTGDSY
 LDGSGFARISFEKQFSNTKRFQELRLVSYNGHIFLQKESQFLCLAVQEGTLVLF
 YDFGSGLKADPLQPPQALTAASKAIQVFLLAGNRKRVLRVERATVFSVDQDN
 MLEMADAYYLGGVPPEQLPLSLRQLFSPGGSVRGCIKGICALGKYVDLKRNLNTT
 GISFGCTADLLVGRMTTFHGHGFLPLALPDVAPITEVVYSGFGFRGTQDNNLLYY
 RTSPDGPYQVSLREGHVTLRFMNQEVETQRFVADGAPHYVAFYSNVTGVWLYV
 DDQLQLVKSHERTTPMLQLQPEEPSRLLLGGLPVSFTFHNFGCISNVFVQRLRG
 PQRVFDLHQNMGSVNVSVGCTPAQLIETSRTAQKVSRRSRQPSQDLACTTPWL
 PGTIQDAYQFGGPLPSYLQFVGISPSHRNRLHLSMLVRPHAASQGLLLSTAPMSG
 RSPSLVFLNHGHFVAQTEGPGPRLQVQSRQHSRAGQWHRVSVRWGMQQIQLV
 VDGSQTWSQKALHHRVPRAERPQPYTLVSGGLPASSYSSKLPVSVGFGSGLKKL
 QLDKQPLRTPTQMVGVTPCVSGPLEDGLFFPGSEGVVTELEPKAKMPYVSLELE
 MRPLAAAGLIFHLGQALATPYMQLKVLTEQVLLQANDGAGEFSTWVTYPKLCD
 GRWHRVAVIMGRDTRLLEVDTQSNHTTGRLPESLAGSPALLHLGSLPKSSTARPE
 LPAYRGCLRKLLINGAPVNVNTASVQIQGAVGMRGCPSGTLALSQKQKALTQRHA
 KPSVSPLLWH

1 gaccttact gcaagctggt tgggggtccg gtggctggcg gagatcccaa tcagacaatc
 61 cagggccagt actgtgacat ctgtacagct gccaacagca acaaggcaca ccctgtgagc
 121 aacgccatcg atggcacgga gcgctggtgg cagagccac ccctgtcccg tggcctggag
 181 tacaatgagg tcaacgtcac actggacctg ggccagggtg tccatgtggc ctatgtgctc
 241 atcaagtttg ccaactcacc tcggcctgac ctctgggtgc tggagcggtc cacagacttc
 301 ggtcacactt atcagccgtg gcagttctt gcctctcca agagggttg ttggagcgg
 361 ttggacctc ggactctaga gcgcacacg caggacgacg acgtcatctg caccacagaa
 421 tactcgcaa tagtgcttt ggagaatggc gagattgtg tgccttggg aaatgggcgc
 481 cctggggcct tgaactctc ctactaccg ttactcgag acttaccac agccaccaac
 541 atcagcttgc ggtttctgcg aaccaacacg ctactgggccc acctcatggg caaggcgtc
 601 cgggacccca cagtcacccg caggtattat tacagcatca aagacatcag cattgtggg
 661 cgctgtgtct gtcattggca cgcagatgtc tgtgacgcca aggaccatt ggatccttc
 721 aggtgcagt gtgcctgcca gcacaataca tgtgagggt cttgtgaccg atgctgtcca
 781 ggcctcaacc agcagccgtg gaagccgcc accacggaca gcgccaatga gtgccagtc
 841 tgcaattgcc acggccatgc ctacgactgt tactacgacc ctgaggtgga tcggcgcaat
 901 gccagccaga accaggacaa cgtgtaccag ggtggagggt tctgcctgga ttgccagcat
 961 cacactacgg gtatcaactg tgagcgtgt ctgcctggct tctccgtgc ccctgaccg
 1021 cctctcgact cacctcatgt ctgtcgccc tgcgactgtg agtcagactt cacggtggg
 1081 acctgtgaag acttgacggg ccgctgttac tgcaggcca acttcacagg agagctatgt
 1141 gctgcctgcg ctgagggcta cacggacttc ccaactgct acctctgcc ttcattct

Figure 1B

1201 cacaatgaca cgagagaaca ggtgcttccc gctggacaaa tegtgaactg tgattgcaat
 1261 gctgcaggga cccagggcaa tgcctgccgg aaggaccaa ggtgggacg gtgtgtctgc
 1321 aaaccaact tccggggtgc cactgtgag ctctgtgctc ctggatcca cgggcctagc
 1381 tgccacccat gccagtgtc cagccctggg gtagccaaca gcctctgtga cccagagtct
 1441 ggccagtga tgtccgcac cggctttgag ggggacaggt gtgaccactg tgccttggc
 1501 tatttccact tccctctctg tcagctgtgt ggctgcagcc cagcaggga cctgcctgaa
 1561 ggctgtgacg aggctggccg ctgccagtgc cgacctggct ttgacggctc tcactgtgac
 1621 cgatgccttc caggatacca tgggtatccc gactgtcacg cttgtgcctg tgacctcgg
 1681 ggggccctgg atcaacagtg tggagtgggc ggtttgtgcc actgccgtcc tggcaacaca
 1741 ggtgccactt gtcaggaatg tagccccggc ttctacggct tcccagctg calccctgc
 1801 cactgtctg ccgatggctc ctgcatata acctgtgacc cgacaaccgg ccagtgtagg
 1861 tctgacccc gagtgacagg actacattgt gatattgtg taccaggcgc ctataacttc
 1921 cctactgtg aagctggctc ttgtatcct gctggtctgg cccagccaa tctgccctt
 1981 cctgagacac aggtcctctg tatgtccgg gctcacgtgg aagggccaa ctgtatcgc
 2041 tgtaaacctg ggtactgggg gctgagcgc agcaacctg aaggctgcac acgctgcagc
 2101 tgtgaccac gaggcacct ggttgaggt actgagtgcc agggcaatgg gcagtgttc
 2161 tgcaaggctc acgtgtgtg caagacctg gcagcctgca aggatggctt ctttggcctg
 2221 gattatctg actactttg ctgccctagc ttaggtgtg atgttggtg tgcctgggt
 2281 cagggtctg aacaaagac aggtgccctg aggtgccgc ctaacacca aggaccacc
 2341 ttagcgagc cagcgaagga ccactactg ccagacctg accacatcg gctggaacta
 2401 gaggggagg ccactccga gggccacgt gtacgtttg gcttcaacc cctggagtt
 2461 gagaacttta gctggagagg ctacgcacac atgatggta tccagcccag gattgtggc
 2521 aggtgaacg tgacctccc tgacctttt cactgtgtt tccgatagt caaccgtga
 2581 tcaaccagc tgaatggga gatctctgt cgtgaagagg gcaagcttc cagctgtacc
 2641 aactgcacag agcagagcca gccagtggct tcccaccca gactgagcc tgccttctc
 2701 actgtcccc agaggggctt tggggaacc tttgtgta acccggcat ctgggcttg
 2761 ctggtcagg ctgaaggtg actctggac tacgtgttc tactgcccag cactactat
 2821 gaggcagctc tctacagca tgaagtaac gaggcctga cctaccgtc ctacgccctg
 2881 cactccacag agaactgtt tctatgtt cactacccc tggatggct ccttcagca
 2941 gctggaactg aggcctgtg tgcctatgac aacagcctg cccggccctg cccacagag
 3001 cagctcagcc cctcacacc accgctggcg acctgctcg gcagtgtat ggacatccag
 3061 ctgagatgg ccgtgcctca gcctggccaa tatgttctg tgggtgaata tgcgggtgag
 3121 gattcacacc aagagatgg agtggtgtg cacacccctc agagagcccc ccagcaagg
 3181 gtgtcaacc tccaccctg cccatagc tccctgtgcc ggagtccggc tgggacacc
 3241 cagcatatc tagccatctt ccactggac tctgaggcta gcatccggt cacagtga
 3301 caagctcact tcttctgca cagctcacc ctggtacctg tggaggagt cagtactga
 3361 tttgtggag cccgggtct ctgtgtgagc agtcatgaa cttcaacc cagcagtgt
 3421 gcctgtctg cctccgatt cccgaagcca ccgagccca tcatcttaa gactgccag
 3481 gtcttgcgc tgcctccga cctgcctctg actcagctc aggagctc accaggtga
 3541 cccccagg gaccacagcc tggccgcca actgcgggtg atcctaagc agaaccacc
 3601 ttgtgcgcc acccccagg cagggtggtc ttaccaccc aggtgccac cctgggccc
 3661 tatgccttc tgtgcacg ctaccagcc gtccacctt ccttccctg ggaggtact
 3721 attaatggt gccgcactg gcagggccac gccaacgcca gctttgtcc tcatgggtat
 3781 ggctgccga cctgtgtgt gtgtgagggt cagacgatg tggatgtac agacaacgag
 3841 ctaccgtga ctgtgcgtg gccagaagg cgggtgctt ggctggacta cgtactatt
 3901 gtccctgagg atgcttac ctccagttac ctccaaggagcctttgga caaatcctat

Figure 1C

3961 gacttcacga gccactgtgc caccagggc taccacatta gcccagcag ctcactcca
 4021 ttctgccga atgccgccac ctcttgtct ctctctaca acaacggggc cctccctgt
 4081 ggctgccacg aggtgggtgc cgtagcccc acgtgcgaac cctcggggg ccagtgtcc
 4141 tgccggggcc acgttattgg cgtgactgt tcccgtgtg ccaccggcta ctgggggttc
 4201 cccaactgca ggccctgtga ctgtggagcc cgcctgtgtg acgagctcac gggccagtgt
 4261 atctgtccac cagcactgt tccccctgac tgcctggctt gccagccaca gaccttgggt
 4321 tgccacccct tgggtgggtg tgaggagtgt aactgctcag ggcccggcgt ccaggagctg
 4381 acggacccta cctgtgacat ggacagcggc cagtgcagat gcagaccac tgtagctgga
 4441 cgtcgtgtg atacctgtgc cccgggcttc tatggctatc ctagtgtgc cccctgtgac
 4501 tgccatgagg caggcaccat ggctagcgtg tgtgacccc tcacaggcca atgccattgc
 4561 aaggagaacg tcaggggctc aagatgtgac cagtgtcgcg tggggacctt ctcttggat
 4621 gctgctaacc ccaagggtg tacccgtgc ttctgttcg ggccacaga gcgtgtggg
 4681 aactctaacc tcgcccga tgagtctgtg gacatggagg gctgggtgt gttgagcagt
 4741 gaccggcagg tggtaaccca cgagcatcgg cctgagatag agctgtgca cgcagatctg
 4801 cgctctgtg ctgacactt ctgagagctg tactggcagg ctccgccctc ctatctggga
 4861 gacagggtgt catcctacgg tggaaacctc cactatgagc tgcactcaga gaccagcga
 4921 ggtgatact tcattcccta cgagagccgg ccggacgtc tctgcaggg caacaaatg
 4981 agcatgcct tcttgaact ggctaccct ccgctggcc aggttcaccg aggacagcta
 5041 cagctggtag aggggaactt ccggcacttg gagactcaca acccgtgtc ccgagaagaa
 5101 ctcatgatgg tcttggccgg cctggagcag ctgcagatcc gtgtctctt ctgcagacc
 5161 tcttcagtg tctcttgcg tagagtggta ctggaggtgg ctgagaggc tggtagggg
 5221 cctccagcca gcaatgtgga actgtgtatg tgccctgcca actaccgtgg ggactcgtgc
 5281 caggatgtg cccctggcta ttaccgggac accaagggtc tcttctagg ccgatgtgtc
 5341 cctgtcagt gccatggcca ttcagatgc tgccttctg gctctggcat ttgtgtggg
 5401 tgccagcaca acacagaagg ggaccaatgt gagcgtgta ggcctggctt tgcagcagt
 5461 gatccagta accctgcac ccatgtgtg agctgccctt gcccttggc agtgccctc
 5521 aataatttg cagacgggtg cgtcttaaga aatggccgaa ccagtgctt ctgcaggcca
 5581 ggctatgtg gtgcctctg cgagcgggtg gcacctggct ttttgggaa cccctgggt
 5641 ctaggcagct cctgtcagcc ctgcgactgc agcggtaatg gagaccccaa catgalttc
 5701 agtactgctg accccctgac ggggtgctgt cgaggtgccc tccgtcacac cactgggccc
 5761 cactgtgaac gctgtgccc aggttctat ggcaatgctt tgtgccagg caactgcacc
 5821 cgggtgtgact gtccccatg tgggacagaa acctgtgatc ccagagtgg acgtgcctg
 5881 tgcaaaagcag gcgtgactgg acaacgtgtg gaccgtgtt tgggaaggata ctctgggtt
 5941 gagcaatgcc agggctgccc ccttgtgccc tgtggaccag ctgccaaggg ctccgagtgc
 6001 caccctcaga gggctcagt tcactgccag ccaggggacca caggaccca gtgcctcag
 6061 tgcccccctg gctactgggg cctccagag aagggtgca ggcgtgcca gtgtcccca
 6121 ggccactgtg acccacacac ggccactgc acctgtccc cggggctcag cggggaacgc
 6181 tgtgacacct gcagccagca gcaccagtg cctgtaccgg gcaagcctg yggccatggc
 6241 atacactgtg aagtgtgtga cactgtgtg gtctcttc tggatgaact cgagcgggt
 6301 ggtgccctcc tccccgtat ccgtgagcag ctgcagggtg tcaatgccag ctccgggcc
 6361 tggggcaggc tgcacaggct gaatgcctcc attgtgacc tgcagagtaa actccggagg
 6421 ccaccgggac cccgtacca ggacgacag cagctacaga ctctagagca gcagagtata
 6481 agccttcaac aggacacgga gaggctgggc agtcaggcca cagggtcca aggtcagga
 6541 ggccagctac tggacaccac agagtccaca ctgggccggg cacagaagtt gttgagct
 6601 gtgcgagctg tgggccgtgc cctgaatgag ctggcatctc gcatgggcca aggatctcca
 6661 ggcatgctt tggaccgtc tggcgagcag ctgcgtggg ctctggctga agtgagcgg

Figure 1D

6721 ctgctctggg atatgcggac gcgtgacctg gggggcccagg gggcagtggc agaggccgaa
 6781 ctggccgaag cccagaggct gatggctcgt gtccaggagc agctgaccag ctctgggag
 6841 gagaaccagt cattggccac acacattcgg gaccagctgg ctacgtatga gtctggcctc
 6901 atggatcttc gtgaggccct gaaccaggcc gttataacca cccgggaggc tgaggaaactc
 6961 aacagccgca accaggaacg ggtgaaggaa gccctgcaat ggaaacagga actgtcccag
 7021 gacaatgcca cctgaaggc cactctcaa gctgccagtc tcatcttggg ccatgtttct
 7081 gagcttctgc agggcataga ccaggctaag gaggacctag agcacctggc ggccagcctg
 7141 gatggagcct ggacaccctt actgaagagg atgcaggcct tttcccctgc cagcagcaag
 7201 gtggacttgg tagaggctgc tgaggctccac gtcagaagc tgaaccagct ggcaatcaac
 7261 ctgtctggca tcatccttgg catcaatcag gaccgcttca tccagagggc tgtggaagcc
 7321 tccaatgcct acagcagcat ccttcaggcc gttcaggctg ccgaggatgc ggcaggccag
 7381 gcaactgaggc agggcagccg cacatggggag atggtggtgc agcggggcct agcagctgga
 7441 gcccggcagc tggtagccaa cagcagtgc ctggaggaga ccatccttgg acaccagggg
 7501 aggctgggccc ttgctcaggc ccgtctgcag gctgcgggga tccagcttca taatgtcttg
 7561 gccaggaaga accagctagc agcccagatc caggaggcac aagccatgct ggccatggac
 7621 acgagcgaga ccagtgaaga gattgctcac gccaaggctg tggctgccga agccctcagt
 7681 acggccacc acgtgcagtc tcagcttcag ggtatgcaga agaattgga gaggtggcag
 7741 agccagctgg gaggcctgca agggcaggac ctgagccagg tggaaaggga tgcaagcagt
 7801 tcagtgtcca cctgggaga gacattgcca cagctgctgg ccaactgag ccgtctagag
 7861 aaccgtggag ttcacaatgc cagcctggct ttgtctgcca acattggtcg tgtgcgcaag
 7921 ctcatgccc aagcccggag tgccggcagc aaggctcaagg tgcctatga gttaactggg
 7981 cgttcagggg tacgactgcg tccccacga gaccttgcg accctgctgc gtacactgcc
 8041 ctcaagtcc acatccagag ccagtgcca gcgcccgaac ctggcaagaa cacggggggac
 8101 cactttgttc tttacatggg cagccgccag gccactgggg actacatggg agtgtctctg
 8161 cgtaatcaga aggtgcactg ggtgtacagg ctaggaaagg ctggcccac aactctcagc
 8221 atcgacgaga acatcgggga gcagtttga gccgtcagca tcgacaggac cctccagtt
 8281 ggccacatgt ctgtcaccgt ggagaaacag atggttcatg agatcaaggg agacacgtg
 8341 gccctggga gcgagggact actcaacctg catcctgacg attttgtct ctacgtggga
 8401 ggatacccca gcaacttcac gcccctgaa cccctccgat tccctggcta cctgggctgc
 8461 attgagtgga aaacactgaa tgaggagggtg gtcagcctct acaatttga gcagacctc
 8521 atgtgggaca cggcagtaga taaacctgt gctcgtcca aggccaccg tgacctatg
 8581 ctacagatg gctcctacct ggatggcagt ggctttgcc gcatcagct tgagaagcag
 8641 ttcagcaaca caaacgctt tgaccaggag ctgcggcttg tgcctacaa tgggatcatc
 8701 ttttctca agcaagagag ccagttctg tgcctggcag tgcaggaagg caccctggg
 8761 ctcttctatg acttcggctc tggcctgaag aaggccgacc cactgcagcc cccacaagcc
 8821 ttgacggcag ccagcaaggc gatccaagt tttctattgg ctggcaatc caaacgtgtg
 8881 ttggtgcgtg tggagcgggc cactgtgtc agcgtagacc aggataacat gctggagatg
 8941 gctgatgcct actacttggg aggdgtgcca cctgaacagc tgccttgag cctacggcag
 9001 ctcttcccc ccggaggctc tgcctggy tgcataagg gtattaagc tctgggcaag
 9061 tacgtggacc tcaaacggtt gaacaccag ggcacagtt tcggctgcac cgtgacctg
 9121 ctagtgggac gcaccatgac tttcacggc cagggcttcc tgccttggc acttctgat
 9181 gtggcaccca tcaccgaagt ggtctattct ggctttggct ttcgtggac ccaggacaac
 9241 aacctgctgt attaccgtac ctccccgat gggccgtacc aggtatccct gagggagggc
 9301 cagctgacac tccgtttat gaaccaagag gtggaaactc aaagggtctt tgcgtatggt
 9361 gctcctact atgtgcctt ctatagcaat gtcacagggg tatggctgta tgtggatgac
 9421 cagctacaac tagtaaagtc tcatgagaga acaactccca tgctccaact acagcccag

Figure 1E

```

9481   gaaccctcac ggcttctcct gggaggcctg cctgtgtctg gtaccttcca caacttcagt
9541   ggctgcatca gcaatgtttt tgtacagcga ctctggggac cācagcgtgt gtttgaccta
9601   caccagaaca tggggagtggt caatgtaagc gtaggctgta caccagccca actcatcgag
9661   acctcaaggg ccacggctca gaaggtttcc cgccgtagtc gacaaccag ccaggacctt
9721   gcctgcacga caccctggct ccttgggact attcaggatg cataccagtt tgggggaccc
9781   ctgcccagtt acctacagtt tgtgggtatc tctccgtccc acaggaatag gctccacctc
9841   tccatgcttg tccgtccaca tggggttcc cagggcctcc tgcctctac agccccatg
9901   tcggggccga gcccttcgtt ggtactctt cāaaccatg gacactttgt cgcacagact
9961   gagggccctg ggccccggct ccaggctccag agtcgccagc actcacgggc tggccagtgg
10021  cacagggtgt ccgtccgctg gggaatgcag cagatccagc ttgtggtgga cggcagccag
10081  acctggagcc agaaggctct ccaccatcgg gtccccaggg cagagcgacc acagccctac
10141  accctctctg taggaggtct tcttgccagc agttacagtt ccaagctccc tgtgtctgtg
10201  gggttcagcg gctgtctgaa gaaattacag ctggataagc agccactgag gacccaacg
10261  caaatggtgg gggcacacc ctgtgtctca ggccccctgg aagatggcct gttcttcca
10321  ggcagtgagg gagttgtcac attagagctc cccaaggcca agatgcccta tgtgagcctg
10381  gagctagaga tgcggccctt ggcagctgct ggctctatct tccacctggg ccaggccctg
10441  gccactccct acatgcagct gaagggtctg acagaacagg tctgtctgca ggcaaatgat
10501  ggggcagggg agttttccac gtgggtgacc taccccaagc ttgtgatgg acggtggcac
10561  cgagtggcag tgatcatggg caggacaca ctccggctgg aggtagacac acagagcaac
10621  cacaccagag gccgtttgcc agagagcttg gctggttctc cagcacttct gcacctcggg
10681  agcctgcca agtcttcaac tgcctggcca gagctccctg cctaccgagg atgcttgagg
10741  aagctgctga tcaatggggc cctgttcaac gtgactgctt ctgtacaaat ccagggggca
10801  gtggggatgc gcggatgccc ctccaggaacc ctagcacttt ccaagcaggg aaaggcacig
10861  acccagaggg acgccaagcc cagtgtctcc ccgtacttt ggcatgagg gttccagac
10921  ctgggggttt gcctacactt tctatgaata acaagtcatt tctggtttac actgtctttt
10981  agaggaaaag gactctgtag aacagatat

```

20056657.doc

Figure 1F

Amino Acid Sequence and Nucleotide Sequence Encoding Human Alpha5 Chain

SGVQLRTPRDLADLAAYTALKFYLQGPEPEPGQGTEDRFVMYMGSRQATGDYM
 GVSLRDKKVHWVYQLGEAGPAVLSIDEDIGEQAFAVSLDRTLQFGHMSVTVER
 QMIQETKGDVAPGAEGLLNLRPDDFVFYVGGYPSTFTPPPLLRFPYRGCIEMD
 TLNEEVVSLYNFERTFQLDTAVDRPCARSKSTGDPWLTGDSYLDGTGFARISFDS
 QISTTKRFEQELRLVSYSGVLFLLKQQSQFLCLAVQEGSLVLLYDFGAGLKKAVP
 LQPPPLTSASKAIQVFLGGSRKRVLRVERATVYSVEQDNDLELADAYYLG
 VPPDQLPPSLRWLFPTGGSVRGCVKGKALGKYVDLKRNLNTTGVSAGCTADLLV
 GRAMTFHGHGFLRLALSNAPLTGNVYSGFGFHSQAQDSALLYRASPDGLCQVS
 LQQGRVSLQLLRTEVKTQAGFADGAPHYVAFYSNATGVWLYVDDQLQOMKPH
 RGPPELQPPPEGPPRLLLGGLPESGTIYNFSGCISNVFVQRLLGPQRFVDFLQONL
 GSVNVSTGCAPALQAQTPGLPRGLQATARKASRRSRQPARHPACMLPPHLRTT
 RDSYQFGGSLSSHLEFVGILARHRNWPSLSMHVLPSSRGLLLFTARLRPGSPSLA
 LFLSNGHFVAQMEGLGTRLRAQSRQSRPGRWHKVSVRWEKNRILLVTDGARA
 WSQEGPHRQHQAHPQPHTLFVGGLPASSHSSKLPVTVGFSGCVKRLRLHGRP
 LGAPTRMAGVTPCILGPLEAGLFFPGSGGVITLDLPGLATLPDVGLELEVRPLAVT
 GLIFHLGQARTPPYLQLQVTEKQVLLRADDGAGEFSTSVTRPSVLCDGQWHLRA
 VMKSGNVLRLEVDQAQSNHTVGPLLAAGAPAPLYLGGLPEPMAVQPWPAYC
 GCMRRLAVNRSPVAMTRSVEVHGA VGASGCPAA

1 tcagggtgc agctgcgcac cccacgggat cttgccgacc ttgctgccta cactgccctc
 61 aagtctacc tgcaggcccc agagcctgag cctgggcagg gtaccgagga tcgcttctg
 121 atgtacatgg gcagccgcca ggccactggg gactacatgg gtgtgtctct gcgtgacaag
 181 aagggtgact ggggtgatca gctgggtgag gcgggccctg cagtccaaag catcgatgag
 241 gacattgggg agcagttcgc agctgtcagc ctggacagga ctctccagt ttgccacatg
 301 tccgtcacag tggagagaca gatgatccag gaaaccaagg gtgacacggg gggccctggg
 361 gcagaggggg tctcaacct gcggccagac gacttctct tctacgtcgg ggggtacccc
 421 agtacctca cggccctcc cctgtctgc tccccggct accggggctg catcgagatg
 481 gacacgtga atgaggagggt ggtcagcctc tacaactcg agaggacctt ccagctggac
 541 acggctgtgg acaggccttg tccccgtcc aagtcgaccg gggaccctg gctcacggac
 601 ggctctacc tggacggcac cggcttcgcc cgcacagct tcgacagta gatcagcac
 661 accaagcgct tcgagcagga gctgcggctc gtgtctaca gcggggtgct cttcttcctg
 721 aagcagcaga gccagttcct gtgcttgcc gtgcaagaag gcagcctcgt gctgtgtat
 781 gactttgggg ctggcctgaa aaaggccgtc ccactgcagc cccaccgcc cctgacctg
 841 gccagcaagg cgatccagggt gttcctgctg gggggcagcc gcaagcgtgt gctggtgcgt
 901 gtggagcggg ccacgggtga cagcgtggag caggacaatg atctggagct ggccgacgcc
 961 tactacctgg ggggcgtgcc gcccgaccag ctgccccga gcctgcgatg gctctccc
 1021 accggaggct cagtccgtgg ctgcgtcaaa ggcatcaagg ccctgggcaa gtatgtggac
 1081 ctcaagcggc tgaacacgac aggcgtgagc gccggctgca ccgccacct gctggtggg
 1141 cgcgccatga cttccatgg ccacggcttc cttgcctgg cgctctgaa cgtggcaccg
 1201 ctacttgca acgtctactc cggcttcggc ttccacagcg cccaggacag tgcctgctc
 1261 tactaccggg cgtccccgga tgggctatgc cagggtgcc tgcagcaggg ccgtgtgagc
 1321 ctacagctcc tgaggactga agtgaact caagcgggt tcgccgatgg tcccccat
 1381 tacgtcgtc tctacagaa tgccacggga gtctggctgt atgtcatga ccagctccag
 1441 cagatgaagc cccaccgggg accaccccc gagctccagc cgcagcctga ggggccccg

Figur 2A

```

1501   aggctcctcc tgggaggcct gcctgagtct ggcaccattt acaacttcag tggctgcatc
1561   agcaacgtct tcgtgcagcg gctcctgggc ccacagcgcg tatttgatct gcagcagaac
1621   ctgggcagcg tcaatgtgag cacgggctgt gcaccgccc tgcaagccca gacccgggc
1681   ctggggccta gaggactgca ggccaccgcc cggaaggcct cccgccgag ccgtcagccc-
1741   gcccggcac ctcctgcat cctgccccca cacctcagga ccaccgaga ctctaccag
1801   ttgggggtt cctgtccag tcacctggag ttgtgggca tcctggccc acataggaaac
1861   tggcccagtc tcctcatgca cgtcctccc cgaagctccc gaggcctcct cctcttact
1921   gcccgctga ggcccggcag cccctcctg gcgctcttc tgagcaatgg ccacttcgtt
1981   gcacagatgg aaggcctcgg gactcggctc gcgcccaga gccgccagcg ctccggcct
2041   ggccgctggc acaaggtct cgtgcgctgg gagaagaacc ggatcctgct ggtgacggac
2101   gggggccggg cctggagcca ggaggggccc caccggcagc accagggggc agagcacccc
2161   cagccccaca cctctttgt gggcggcctc ccggccagca gccacagctc caaacttccg
2221   gtgaccgtcg gggtcagcgg ctgtgtgaag agactgaggc tgcacgggag gcccttggg
2281   gccccacac ggatggcagg ggtcacacc tgcatttgg gccccctgga ggcgggcctg
2341   ttctcccag gcagcggggg agttatcact ttagacctcc caggagctac actgcctgat
2401   gtgggcctgg aactggagggt gcggcccctg gcagtcaccg gactgatctt ccacttggc
2461   caggcccga cgtccccccta ctgcagttg caggtgaccg agaagcaagt cctgtgcgg
2521   gcggatgacg gagcagggga gttctccacg tcagtgacc gccctcagt gctgtgtgat
2581   ggccagtggc accggctagc ggtgatgaaa agcgggaatg tgctccggt ggaggtggac
2641   gcgcagagca accacaccgt gggccccttg ctggcggctg cagctggtgc ccagcccct
2701   ctgtacctcg ggggcctgcc tgagcccatg gccgtgcagc cctggcccc cgcctactgc
2761   ggctgcatga ggaggctggc ggtgaaccgg tccccgtcg ccatgactcg ctctgtggag
2821   gtccacgggg cagtgggggc cagtggctgc ccagccgct aggaacagc caacccggc
2881   ccctgtcag gccctgcag ctgcctcaca ccgcccttg tgctgcctc ataggtgtct
2941   attggactc taagctctac gggtgacaga tctgtttct gaagatggt taagttag
3001   ctcttaaac gaaagaataa aatactgcaa aatgtttta tattggccc ttccacccat
3061   tttaattgt gagagattg tcaccaatca tcactggtc ctcttaaaa attaaaaagt
3121   aacttctgtg taaaaaaaaa a

```

20059772.doc

Figure 2B

Amino Acid Sequence and Nucleotide Sequence Encoding Murine Beta2 Chain

MEWASGEPGRGRQGQPLPWELRLGLLLSVLAATLAQAPSLDVPGCSRGS
 CYPATGDLVGRADRLTASSTCGLHSPQPYCIVSHLQDEKKCFLCDSSRP
 FSARDNPNSHRIQNVVTSFAPQRRTAWWQSENGVPMVTIQLDLEAEFHFT
 HLIMTFKTRPAAMLVERSADFGRTWHVYRYFSYDCGADFPGIPLAPRR
 WDDVVCESRYSEIEPSTEGEVIYRVLDPAIPDPYSSRIQNLLKITNLRVNL
 TRLHTLGDNLLDPRREIREKYYYALYELVIRGNCFYGHASQCAPAPGAP
 AHAEGMVHGACICKHNTRGLNCEQCQDFYQDLPWHPAEDGHTHACRKC
 ECNGHTHSCHFDMAVYLASGNVSGGVCDGQCQHNAGRHCEFCRPFYR
 DPTKDMRDPVCRPCDCDPMGSQDGGRCDSHDDPVLGLVSGQCRCKEH
 VVGTRCQQRDGGFGLSASDPRGCQRCQNSRGTVPGSSPCDSSSGTCFC
 KRLVTGHGCDRCLPGHWGLSHDLLGCRPCDCDVGGALDPQCDEATGQC
 PCRQHMIGRRCEVQPGYFRPFLDHLTWEAAQAQGVLEVVERLVTNRE
 TPSWTGPGFVRLREGQVEFLVTSLPRAMDYDLLLLRWEPQVPEQWAELE
 LMVQRPGPVSAHSPCGHVLPKDDRIQGMLHPNTRVLVFPRPVCLEPGISY
 KLKLLKLGTTGGRAQPETSYSGLLIDSLVLQPHVLVLEMFSGGDAAALERR
 TTFERYRCHEEGLMPKAPLSETCAPLLISVSALIYNGALPCQCDPQGSLS
 ECSPHGGQCRCKPGVVGRRCDVATGYGFGPAGCQACQCSPDGALSA
 LCEGTSGQPCRPGAFLRCDHCQRGQWGFNCRPCVCNGRADECDTHT
 GACLGCRDYGGEHCERCIAGFHGDPRLPYGGQCRPCPCPEGPGSQRHFA
 TSCHRDGYSQQIVCHCRAGYTGLRCEACAPGPGDPSKPGGRCQLCECSG
 NIDPMDPDACDPHTGQCLRLHNTEGPHCGYCKPGFHGQAARQSCHRCT
 CNLLGTDPRRCPSTDLCHCDPSTGQCPCLPHVQGLNCDHCAPNFWNFTSG
 RGCQPCACHPSRARGPTCNEFTGQCHCHAGFGGRTCSQCQELYWGDPL
 QCRACDCDPRGIDKPQCHRSTGHCSRPVSGVSRCDQCARGFSGVFPAC
 HPCHACFGDWDRVVQDLAARTRLEQWAQELQQTGVLGAFESSFLNMQ
 GKLGMVQAISARNASAASTAKLVEATEGLRHEIGKTTERLTQLEAELTA
 VQDENFNANHALSGLERDGFALNLTLRQLDQHLEILKHSNFLGAYDSIRH
 AHSQSTEAEERRANASTFAVPSVSNADTRRRTEVLMGAQKENFNQHL
 ANQQALGRLSAHAHTLSLTGINELVCGAPGDAPCATSPCGGAGCRDEDG
 QPRCGGLGCSGAAAPADLALGRARHSQAEQLRALVEGGGILSRVSETRR
 QAEAAQQAQAALDKANASRGQVEQANQELRELIQNVKDFLSQEGADP
 DSIEMVATRVLDISIPASPEQIQLASEIAERVRLADVDTLAHTMGDVRR
 AEQLLQDAHRARSRAEGERQKAETVQAALAEAQAQAQAQAQAQAQAQAQA
 DTQNTQTLQRVQERMAGAEKSLNSAGERARQLDALLEALKLKRAGNSL
 AASTAEETAGSAQSRAREAEKQLREQVGDQYQTVRALAERKAEGVLA
 QARAEQLRDEARDLLQAAQDKLQRLQLEGTYEENERALEGKAAQLDG
 LEARMRSVLQAINLQVQIYNTCQ

1 aaaggcctc gagcttccaa gtaatcttg cttgatctcc aagagtctgt catagcgttg
 61 cactcaaacg aagccgtacg acctgaacca acctcttcg cctgtgtcc aggggtcgg
 121 gtggnnngcg cctagtgggt gcgcgcattc caaccctcgc tcccggtcgc ccaggcgact
 181 ggaaagtccg gcgtggataa atagtcacaa gattcggatt cacttgttc tgggtgtcca
 241 gagtctgtca cccagaacct atcctctggg taactgagta gccacagccc attttaatca

Figure 3A

301 ggaaacaggc aacctttctc gcaaccatt tgctggagtg cttatggacg gtcgagttcc
 361 tcggagttct gtttcaggca gtagtgcgtg gcctttccag tatctccgag agctcagttc
 421 tagtctatcc ttggggcgtc ctaaaccctt ccacaggtag aatagaattc tagcttgac
 481 ctttcccatc catctcccga ctgatgctgt aacctggga gccccgaggc tgattigtgg
 541 ttcccatagt gacaccagga caaaggccat aagctcttc catctgctt cctgatacac
 601 aaagatcaca aacctctga ttacctctg ccaccggcca acaccagag cctcttct
 661 gtccctgaa tgccatgctt gccagcaac cctggttcac atcgggactt aaggatccg
 721 atgaagatat gtggaccagg atgctctgtc ttgagcagc ctacttaaat ttcttttg
 781 atgtccctt ttagtcttc gaactaagct gcttcttgc taagtacaca tctgctaaat
 841 aaacttcagc ttaaaaagaa agtggatgaa gtaaccaaag tctggttctt aggatgaggg
 901 ttgtctgcag cgggcagggg tatgtaggg grtgggtgct taccctcagt tataatccta
 961 ttttagatcc actccgtgtt ttacttctt ccttgcctt ccaactttac tcaaagtcgt
 1021 cagagtctct cagattgttg aggagtgtact gctaggtccg accctggaca gattgagggc
 1081 ctggaggagc accagcccag taccacacg gtcgggtcag catcagcccc aagggagggtg
 1141 gtgggcttgc gtctgtggac tctttatctc tctttatctc tattttactt ttcttcagga
 1201 tggagtgggc ctacaggaa ccaggagggg gcaggcagg acagccttg ccatgggaac
 1261 ttgcctggg cctacttcta agtggtagg gggcctgtg aggcctaagg ttgtgggatg
 1321 tgatgtagg tccagggggt gcaggctgtt cccaggggcc caagggggtg ggtagtccac
 1381 caggagtctt gctgagctga ttgacctt gtcctcagt ctgggtgcca cattggcccc
 1441 ggccccgtc ttgatgtac ctggctgtc tcgaggaagc tgctatccag ccaccggtga
 1501 cctgttggtg ggccgtgagg acagactgac ggctcatcc acgtgtggt tgcatagccc
 1561 tcaacctac tttattgtca gtcacctga ggtgcttct gggccccaga ggagagggt
 1621 gggtcagggt ggggtcggcc ccagctaagg tacctatctt acactccacc caatccagga
 1681 cgaagaagag ttttctgt gtgactccc agtcccttc tctgctcag acaacccaaa
 1741 tagtcatcg atccagaatg tagtcaccag ctttgcgcca caacgccga cggcctggtg
 1801 gcaatcggag aacggtgagc cctgagtag gtcacagga tgactagggc ttgtaaccag
 1861 taaccgaga acctgaccc cttatctctg ctgcagggtt tccaatggtc accatccaac
 1921 tggacctgga agctgagttt catttacc accctattat gacgttcaag gtgcctgtc
 1981 gtcagcgaac ccgctgatt ttgcttctt tctcagtag ccctaacaga gtcctagctc
 2041 tacaacgaag ctccctgag ctctgtgtt gtgctctatg tgtgaagcat ggtcacgtcc
 2101 tgcattgctt ccatagttga acacctctgc acatgctctc ttgtgcccc ttctagggt
 2161 aagtcagata cagtctctt gggtctctg gtattttaac ctgctgtca gaggtggctg
 2221 tcttccctgg tctgatcatg gctggctt cctagtctt ccatgtgtc tgagatgctc
 2281 agcagtgtc atgactaagc agagctctc gtaacctagg ctggactgaa gtcgtgttc
 2341 tgctagtcag acatgtctc cttcccatc cagacgttc ggctgtgtc tatgtgtg
 2401 gagcgttct cagacttgg ccgacctgg caggtgtacc gatattttc ctatgactgc
 2461 ggggtgact tcccgggaat ccactggcc ccgcccgtc gctgggatga ttagtgtgt
 2521 ggtcccgct actcagaaat cgagccgtc acggaaggcg aggttaaggc tgggaccag
 2581 ctagtgggt ctgtgatgga cgtggacgag gttcattatc tgtggacttc ttgctgtct
 2641 aggtcatcta tctgtgtctg gacctgtc ttccatccc agaccctac agctcacgga
 2701 ttgagagtga gtgttctact atggacattg gcacagtctc agtgtccga tgggactatt
 2761 tggggcctca gtaactattt taggtgtctc ctagggcaaa tgccaagccc agtttagctc
 2821 tgggagcaat agaaaagagg tctccaagg tgacctggc agctgcaacc aatggtggca
 2881 ctggtgggga cgaggcaaca agggggcacc tcttaggtg gacgagacc tcttccctt
 2941 cttagacctg ttgaagatca ccaacctac agtgaacta acccggttc acacactggg
 3001 agacaacttg cttgaccac ggaggagat ccgggaaaaa tactattatg ctctctatga

Figure 3B

3061 acttgtcatc cgtggcaact gcttctgcta tggccacgcc tcacagtgtg cgcctgcacc
3121 agggggcgccg gcccatgctg agggcatggg aagggaactc ggatgactgg aacagggttg
3181 ccggggaggg acaggcattt ctatgtgtg cgtcaacct cccctcgtat ctgcacagg
3241 acacggagcc tgtatctgca agcacaatac tegtggactc aactgtgagc agtgtcagga
3301 ttctatcag gaccttcctt ggcaccctgc agaggacggc catactcacg cctgtcggag
3361 tgagtggac acagaactct aaccgggctg tgcctgggt gagccaaaaa gctagtgtg
3421 caagccctaa atacctaggc yttgtctga aggtatcag gcctgatgg cctcaacca
3481 tgtgctctgc tacagtcaa agtggagct tgaagtaag ctgcaccaca aattctagct
3541 atggtacat aggtgatga tactagcccc actcgcgtgt ccttacctag gacctgttt
3601 ccaattgttc ttgcctct ctccagagt tgagtgaac gggcatactc atagctgcca
3661 ctttgacatg gctgtctacc tggcatctgg aaatgtaagt ggaggcgtat gcgatgggtg
3721 tcagcacaac acagctgggc gccatttga gttctccgg ccttctct accgtgacc
3781 caccaaggac atcggggacc cagctgtgtg cgtcgttaag gctgggattg ggcagaggc
3841 tgantctcag aactagaact aggaacgtgg attatagac gtcccagga ttggtgtgt
3901 cagggtctgg ggtagaacca gaacaggga agggaaggct caggatgtgc actgcgatgg
3961 ggtgacttta tactctctt ttctcagct tgtgactgt accctatggg ttctcaagt
4021 ggtggctgct gtgatttca tgatgacct gtgctaggac tggctcagg ccagtgtcgc
4081 tgcaaaagac acgtggttg cactcgtgc cagcaatgcc gtgatggctt cttggactt
4141 agtgccagt accctcagg gtgcccagct atgtccctc tgcctaact cctgtgtcga
4201 ccttaacc caggcctctt gttctgatg cagtgaacc tgccttact cctaaaaatg
4261 ggctgcttt cactacaggt tgcagtgta atcacgggg cacagtgcct gggagctccc
4321 cttgtgactc cagtgtgga acctgttct gcaagcgtct ggtgaccgga catggctgtg
4381 accgctgtct ggtacgactg agggatctgg ggtcctggga tctgggtt gtctcaag
4441 cacatgggca aagtccagt ggtggacact gagagcctag agtctagtc tgaagaca
4501 gcgtctggc tggcaggtca agggctaga ccagtgtct ggggcttgc attcaccagt
4561 ccaagtggta aattgctgac tactgtgtg gtggcaagga ggtcgttcc tggctccag
4621 caattcctt tcctagcct ggccactggg gcctgagcca tgacctgtg ggtgccgtc
4681 cctgtgactg tgatgtgggc ggtgccttg atcctcagt agtattgta cagggtctg
4741 ggaggtggat ggggaaggca agcatgggc ctttgtaac cacagcattc ctccaggtg
4801 atgaggccac cgtcagtc cgtgccgc aacacatgat tggcgcgcc tgcgaacaa
4861 tgcagcctg ctactccgg cctttctgg accatttaac ctggaggct gaggctgcc
4921 aagggcagt ggggactca tatgatgtg gtgtgtgt agagaggagg ggtgtgtg
4981 ggtgtcttg ggggtctagg ttgctattca gtctgggg aggtctggc acaggacatg
5041 gtgtttggg ctggctgtg cagaagagac agtggttcac ctgacacctc atctctgct
5101 tgaactgatt gactcagggt cttgaggtg gtagagcggc tggtagcaa ccgagagact
5161 ccgtctgga ctggcccagg cttgtgcgg ctgcgagaag gtcaggaagt ggagttcctg
5221 gtgacctt tgctagggc catggactat gacctgtac tgcgtggga gcccaggtt
5281 agacctgtg gtggtgacc tgtgctgaca ttctgggtgt ggaagcacc tctccactgt
5341 cctctctcc caggtccctg agcaatgggc agagctggaa ctgatgtgc agcgtccggg
5401 gcctgtgtc gtcacagtc cgtgcgggca tgtgctgcct aaggatgacc gcattcaggg
5461 gatgcttcac ccaaacacca ggtgaggcgg nggtaagga ttgccacag acctcctgaa
5521 agactgacat tgcgtgtgt gtctctct ttaagtcct cctcctggct gctgtctc
5581 aggtccatg ctgtgactca caggaaagac atagataaca catggcctgc ttctcaagg
5641 gtataagtt cagaaggcaa gacattaatt ggtctgtac tccgaaacag ccttatgat
5701 gtgacagtg cagtggcgt agatatgaa ctggactagt taaggtttg ttacattta
5761 gaagtaatta ttctgtat cttttctc actactctc gctctctc tctctctc

Figure 3C

5821 tcttttctct tcttttctct acttttctct tcttactct actagtctaa acttatcttc
5881 tgctcttacc tctctctctc tctcaacctg agacaggggt tctctgtata gccccagggt
5941 gtcttggaac tcactac

20059807.doc

Figure 3D

Amino Acid Sequence and Nucleotide Sequence Encoding Human Beta2 Chain

MELTSTERGRGQPLPWELRLPLLLSVLAATLAQAPAPDVPGCSRGSYCYPATADLL
 VGRADRLTASSTCGLNGRQPYCIVSHLQDEKKCFLCDSRRPFSARDNPHTHRIQN
 VVTSFAPQRRAAWWQSQNGIPAVTIQLDLEAFHFTHLIMTFKTRPAAMLVERS
 ADFGRTWVHYRYFSYHCGADFPVPLAPPRHWDDVVCESRYSEIEPSTEGEVIY
 RVLDPAPIPDYSSRIQNLLKITNLRVNLTRLHTLGDNLLDPRREIREKYYYALYE
 LVVRGNCFCYGHASECAPAPGAPAHAEAGMVHGACICKHNTRGLNCEQCQDFYR
 DLPWRPAEDGHSACRKCRRHGHTHSCHFDMAVYLGSGNVSGGVCDGCGHNT
 AWRHCELCRPFYRDPTKDLRDPVCRSCDCDPMGSDGGRCDSDHDDPALGLV
 SGQCRCKEHVVGTRCQQCRDGFGLSISDPSGCRRCQCNCARGTVPGSTPCDPNS
 GSCYCKMLVTGRGCDRCLPGHWGLSLDLLGCRPCDCDVGGALDPQCDEGTGQC
 HCRQHMVGRCEQVQPGYFRPFLDHLIWEAENTRGQVLDVVERLVTGETPSW
 TSGSFVRLQEQTLLEFLVASVPNAMDYDLLRLLEPQVPEQWAELELIVQRPQV
 PAHSLCGHLVPRDDRIQGTLPQHARYLIFPNPVCLEPGISYKLHLKLVRTGGSQAQ
 ETPYSGPGLLIDSLVLLPRVLVLEMFSGGDAAALERQATFERYQCHEEGLVPSKT
 SPSEACAPLLISLSTLIYNGALPCQCNPQGSLSSECNPHGGQCLCKPGVVGRRCDT
 CAPGYYGFGPTGCQACQCSPRGALSSLCERTSGQCLCRTGAFGLRCDACQRGQ
 WGFPSRPCVCNNGHADECNTHTGACLGCRDLTGGEHCERCIAGFHGDPRLPYG
 AQCRPCPCPEGPGSQRHFATSCHQDEYSQIVCHCRAGYTGLRCEACAPGQFGD
 PSRPGGRCQLCECSGNIDPMDPDACDPHPGQCLRLHHTEGPHCAHSPGFHGGQ
 AARQSCHRCTCNLLGTNPQQCPSPDQCHCDPSSGQCPCLPNVQALAVDRCAPNF
 WNLTSGHGCQPCACLPSPGPTCNEFTGQCHCLCGFGGRTCSQCQLHWGDPG
 LQCHACDCDSRGIDTPQCHRFTGHCTCRPGVSGVRCDCARGFSGIFPACHPCH
 ACFGDWDRVVQDLAARTQRLEQRAQELQQTGVLGAFESSFWMQEKLGIVQGI
 VGARNTSAASTAQLVEATEELRREIGEATEHLTQLEADLTDVQDENFNANHALS
 GLERDRLALNLTLRQLDQHLDLLKHSNFLGAYDSIRHAHSQSAEAERRANTSAL
 AVPSPVNSASARHRTEALMDAQKEDFNSKHMANQRALGKLSAHTHTLSLTDIN
 ELVCGAQGLHHDRTSPCGGAGCRDEDGQPRCGGLSCNGAAATADLALGRARHT
 QAEQRALAEGGSILSRVAETRRQASEAQQRAQAALDKANASRGQVEQANQEL
 QELIQSVKDFLNQEGADPDSIEMVATRVLSEIPASAEQIQHLAGAIAERVRLAD
 VDAILARTVGDVRRAEQLLQDARRARSWADEKQKAETVQAALAEAQAQAGIA
 QGAIRGAVADTRDTEQTLYQVQERMAGAERALSAGERARQLDALLEALKLKR
 AGNSLAASTAETAGSAQGRAQAEQLLRGPLGDQYQTVKALAERKAQGVLA
 QARAEQLPDEARDLLQAAQDKLQRLQELEGTYEENERALESKAAQLDGLEARM
 RSVLQAINLQVQIYNTCQ

1 ccgcccggtg ttgcgtcct tccagaatc cgctccggcc ttccttctt gccgcgattc
 61 ccaactttgc tcaaagtcgc cggactctaa gctgtcggag ggaccgctgg acagacctgg
 121 gaactgacag agggcctgga gggaaatagg ccaaagacc acaggatgga gctgacctca
 181 accgaaagag ggaggggaca gcctctgcc tgggaacttc gactgcccct actgctaagc
 241 gtgctggctg ccacactggc acaggcccct gcccgggatg tccctggctg ticcagggga
 301 agctgctacc ccgccacggc cgacctgctg gtgggccgag ctgacagact gactgctca
 361 tccacttggt gcctgaatgg ccgccagccc tactgcatcg tcagtcacct gcaggacgaa
 421 aagaagtgt tctttgtga ctcccggcgc ccttctctg ctgagacaaa cccacacacc

Figure 4A

481 catcgcatcc agaatgtagt caccagcttt gcaccacagc ggccgggcagc ttggtggcag
 541 tcacagaatg gtatccctgc ggtcaccatc cagctggacc tggaggctga gtttcattc
 601 acacacctca ttatgacctt caagacattt cgcctgctg ccatgctggt cgaacgctca
 661 gcagactttg gccgcacctg gcatgtgtac cgatatttct cctatcactg tggggctgac
 721 ttcccaggag tcccactagc acccccacgg cactgggatg atgtagtctg tgagtcccgc
 781 tactcagaga ttgagccatc cactgaaggc gaggtcatct atcgtgtgct ggaccctgcc
 841 atccctatcc cagaccctca cagctcacgg attcagaacc tgttgaagat caccaacctc
 901, cgggtgaacc tgactcgtct acacacgttg ggagacaacc tactcgaccc acggaggagg
 961 atccgagaga agtactacta tgccctctat gagctggttg tacgtggcaa ctgcttctgc
 1021 tacggacacg cctcagagtg tgcacccgcc ccaggggcac cagcccatgc tgaggggcatg
 1081 gtgcacggag cttgcatctg caaacacaac acacgtggcc tcaactgcga gcagtgtcag
 1141 gatttctatc gtgacctgcc ctggcgctcg gctgaggacg gccatagtca tgccctgtagg
 1201 aagtgtgatc ggcatgggca caccacacgc tggcacttcg acatggccgt atacctcgga
 1261 tctggcaatg tgagtggagg tgtgtgtgat ggatgtcagc ataacacagc gtggcgccac
 1321 tgtgagctct gtcggccctt ctctaccgt gacccaacca aggacctgcg ggatccggct
 1381 gtgtgccgct cctgtgattg tgaccccatg ggttctcaag acgggtggtcg ctgtattcc
 1441 catgatgacc ctgcactggg actggtctcc ggccagtgtc gctgcaaga acacgtggtg
 1501 ggcatcgct gccagcaatg ccgtgatggc ttcttgggc tcagcatcag tgacctgct
 1561 ggggtccggc gatgtcaatg taatgcacgg ggcacagtgc ctgggagcac tcttgtgac
 1621 cccaacagtg gatcctgtta ctgcaaacgt ctagtactg gacgtggatg tgacctgct
 1681 ctgctggcc actggggcct gagcctcgac ctgctcggt gccgcccctg tgactcgac
 1741 gtgggtggtg ctttgatcc ccagtgtgat gagggcacag gtcaatgcca ctgccgccag
 1801 cacatggtg ggcgacgctg tgagcagggt caacctggct acttccggcc ctcttgagc
 1861 cacctaattt gggaggctga gaacaccga gggcagggtc tcatgtggt ggagcgccg
 1921 tgacccccc gggaaactcc atcctggact ggctcaggct tctgctgact acagggaagt
 1981 cagacctgg agttcctggt ggccctctg ccgaacgcga tggactatga cctgctgctg
 2041 cgcttagagc ccagggtccc tgagcaatgg gcagagttgg aactgattgt gcagcgtcca
 2101 gggcctgtgc ctggccacag cctgtgtggg calttgggtc ccagggatga tgcattcaa
 2161 gggactctgc aaccacatgc caggtacttg atatttcta atcctgtctg ccttgagcct
 2221 ggtatctctt acaagctgca tctgaagctg gtacggacag ggggaagtgc ccagcctgag
 2281 actccctact ctggacctgg cctgctcatt gactcgctgg tctgctgccc ccgtgtcctg
 2341 gtgctagaga tgtttagtgg ggggtgatgct gctgccctgg agcgccaggc caccttgaa
 2401 cgctaccaat gccatgagga gggctgtggt ccagcaaga ctctccctc tgaggcctgc
 2461 gcacccctcc tcatcagcct gtccaccctc atctacaatg gtgccctgcc atgtcagtgc
 2521 aacctcaag gttcactgag ttctgagtgc aacctcatg gtggtcagt cctgtgcaag
 2581 cctggagtgg ttggcgccg ctgtgacacg tgtgccctg gctactatgg ctttgcccc
 2641 acaggctgtc aagcctgcca gtgcagccca cgaggggcac tcagcagtct ctgtgaagg
 2701 accagtggc aatgtctctg tgaactggt gccttgggc ttcgtgtga cgctgccag
 2761 cgtggccagt ggggattccc tagctgccgg ccatgtgtct gcaatgggca tgcagatgag
 2821 tgcaacaccc acacaggcgc ttgcctgggc tgcctgata tcacaggggg tgagcactgt
 2881 gaaagtgca ttgctggtt ccacggggac ccacggctgc catatggggc gcagtggcg
 2941 cctgtccct gtcctgaagg ccctgggagc caacggcact ttgctactc ttgccaccag
 3001 gatgaatatt cccagcagat tgtgtgccac tgcggggcag gctataggg gctgcgatgt
 3061 gaagctgtg cccctgggca gtttggggac ccatcaaggc caggtggccg gtgccaaactg
 3121 tgtgagtga gtgggaacat tgaccaatg gatcctgatg cctgtgaccc acacccggg
 3181 caatgcctgc gctgtttaca ccacacagag ggtccacact gtgccacac gaagcctggc

Figure 4B

3241 ttccatggcc aggtgcccc gcagagctgt caccgctgca catgcaacct gctgggcaca
 3301 aatccgcagc agtgcctatc tctgaccag tgccactgtg atccaagcag tgggcagtgc
 3361 ccatgcctcc ccaatgtcca ggccctagct gtagaccgct gtgccccaa cttctggaac
 3421 ctcaccagtg gccatggttg ccagccttgt gcctgcctcc caagcccga agaaggcccc
 3481 acctgcaacg agttcacagg gcagtgccac tgctgtgctg gctttggagg gcggacttgt
 3541 tctgagtgcc aagagctcca ctggggagac cctgggttgc agtgccatgc ctgtattgt
 3601 gactctctg gaatagatac acctcagtgt caccgcttca caggctactg cacgtgccgc
 3661 ccaggggtgt ctggtgtgct ctgtgaccag tgtgcccgtg gcttctcagg aatcttct
 3721 gcctgccatc cctgccaatgc atgcttcggg gattgggacc gagtgggtgca ggacttgga
 3781 gcccgtacac agcgccatga gcagcgggag caggagtgtc aacagacggg tgtgctggg
 3841 gcccttgaga gcagcttctg gcacatgcag gagaagctgg gcattgtgca gggcatcgt
 3901 ggtgcccgtc acacctcagc cgcctccact gcacagcttg tggaggccac agaggagctg
 3961 cggcgtgaaa ttggggaggc cactgagcac ctgactcagc tcgaggcaga cctgacagat
 4021 gtgcaagatg agaacttcaa tgccaacct gactaagtgt gtctggagcg agataggctt
 4081 gcaactaatc tcactgtcg gcagctcgac cagcatcttg acttctcaa acattcaaac
 4141 ttctgggtg cctatgacag catccggcat gccatagcc agtctgcaga ggcagaacgt
 4201 cgtgccaata cctcagccct ggagtagctt agccctgtga gcaactcggc aagtgtcgg
 4261 catcggacag aggcactgat ggatgctcag aaggaggact tcaacagcaa acatagggc
 4321 aaccagcggg cacttggaac gctctctgcc cataccaca cctgagcct gacagacata
 4381 aatgagctgg tgtgtggggc ccagggattg catcatgatc gtacaagccc ttgtgggggt
 4441 gccggctgtc gagatgagga tgggcagccg cgtgtgtggg gcctcagctg caatggggca
 4501 gcggctacag cagacctagc actgggcccg gcccgccaca cacaggcaga gctgcagcg
 4561 gcactggcag aaggtggtag catctcagc agagtggctg agactcgtc gcaggcaagc
 4621 gaggcacagc agcgggcccc ggagccctg gacaaggcta atgctccag gggacagggt
 4681 gaacaggcca accaggaact tcaagaactt atccagagt tgaaggactt cctcaaccag
 4741 gagggggctg atcctgatag cattgaaatg gtggccacac ggggtgctga gctctccatc
 4801 ccagctcag ctgagcagat ccagcacctg gcgggcgcga ttgcagagcg agtccggagc
 4861 ctggcagatg tggatgcgat cctggcacgt actgtaggag atgtgcgtcg tccgagcag
 4921 ctactgcagg atgcacggcg ggcaaggagc tgggctgagg atgagaaaca gaaggcagag
 4981 acagtacagg cagcactgga ggaggcccag cgggcacagg gtattgccc ggggtgccatc
 5041 cggggggcag tggctgacac acgggacaca gaggagaccc tgtaccaggt acaggagagg
 5101 atggcaggtg cagagcgggc actgagctct gcagggtgaaa gggctcggca gttggatgt
 5161 ctctggagg ctctgaaatt gaaacgggca ggaaatagtc tggcagcctc tacagcagaa
 5221 gaaacggcag gcagtgccca gggctgtgcc caggaggctg agcagctgtc acgcggctc
 5281 ctgggtgatc agtaccagac ggtgaaggcc ctgctgagc gcaaggccca aggtgtgctg
 5341 gctgcacagg caagggcaga acaactgccg gatgaggctc gggacctgtt gcaagccgt
 5401 caggacaagc tgcagcggct acaggaattg gaaggcacct atgaggaaaa tgagcgggca
 5461 ctggagagta aggcagccca gttggacggg ttggaggcca ggatgcgcag cgtgttcaa
 5521 gccatcaact tgcaggtgca gatctaac acctgccagt gacctgcc caaggcciac
 5581 cccagtctct agcactgccc cacatgcatg tctgcctatg cactgaagag ctcttgccc
 5641 ggcagggccc ccaataaacc agtgtgaacc ccaaaaaaa aaa

Figure 4C

Amino Acid Sequence and Nucleotide Sequence Encoding Gamma3 Chain

MAAAALLLGLALLAPRAAGAGMGACYDGAGRPQRCLPVFENAAFGRLAQASH
 TCGSPPEDFCPHVGAAGAGAHQCQRCDADPQRHHNASYLTDHFSQDESTWWQS
 PSMAFGVQYPTSVNITLRLGKAYEITYVRLKFHTSRPESFAIYKRSRADGPWEPY
 QFYASASCQKTYGRPEGQYLRPGEDERVAFACTSEFSDISPLSGGNVAFSTLEGRPSA
 YNFEESPGLQEWTSTELLISLDRNLNTFGDDIFKDPKVLQSYYYAVSDFSVGGRC
 KCNGHASECGPDVAGQLACRCQHNTTGTDCERCLPFFQDRPWARGTAEAAHEC
 LPCNCSGRSEECTFDRELFRSTGHGGRCHHCRDHTAGPHCERCQENFYHWDPR
 MPCQPCDCQSAGSLHLQCDDTGTCAKPTVTGWKCDRCLPGFHSLSSEGGCRPCT
 CNPAGSLDTC DPRSGRCPCKENVEGNLCDRCPGTGNLQPHNPAGCSSCFYGH
 SKVCASTAQFQVHHLSDFHQGAEGWWARSVGGSEHSPQWSPNGVLLSPEDEEE
 LTAPGKFLGDQRFSGYQPLILTFRVPPGDSPLPVQLRLEGTGLALSRLHSSLSGPQ
 DARASQGGRAQVPLQETSEDVAPPLPFHFQRLLANLTSRLRVSPGSPAGPVF
 LTEVRLTSARPGLSPASWVEICSCPTGYTGQFCESCAPGYKREMPQGGPYASCV
 PCTCNQHGTCDPNTGICVCSHHTEGPSCERCLPGFYGNPFAGQADDQCPCPCGQ
 SACTTIPESGEVVCTHCPPGQGRRCVCDGFFGDPLGLFGHPQPCHQCQCSGN
 VDPNAVGNCDPLSGHCLRLCHNTTGDHCEHCQEGFYGSALAPRPADKCMPCSC
 HPQGSVSEQMPCDPVTGQCSCLPHVTARDCSRCPYGFDDLQGRGCRSCKCHPL
 GSQEDQCHPKTGQCTCRPGVTGQACDRCLGFFGSSIKGCRACRCSPLGAASAQ
 CHYNGTCVCRPGFEGYKCDRCHYNFFLTADGTHCQCPSCYALVKEETAKLKA
 RLTLTEGWLQGSDCGSPWGPLDILLGEAPRGDVYQGHLLPGAREAFLEQMMG
 LEGAVKAAREQLQRLNKGARCAQAGSQKTCTQLADLEAVLESSEEEILHAAAIL
 ASLEIPQEGPSQPTKWSHLAIEARALARSHRDTATKIAATAWRALLASNTSYALL
 WNLLEGRVALETQRDLEDYQEVQAAQKALRTAVA EVLPEAESVLATVQQVG
 ADTAPYLALLASPGALPQKSRAEDLGLKAKALEKTVASWQHMAATEARTLQTA
 AQATLRQTEPLTMARSRLTATFASQLHQGARAALTQASSSVQAATVTVMGART
 LLADLEGMKLQFPRPKDQAALQRKADSVSDRLADTRKKTQAERMLGNAAPL
 SSSAKKKGREAEVLAKDSAKLAKALLRERKQAHRRASRLTSQTQATLQQASQQ
 VLASEARRQELEEAEVVGAGLSEMEQQIRESRISLEKDIETLSELLARLGSLDTHQ
 APAQALNETQWALERLRLQLGSPGSLQRKLSLLEQESQQQELQIQGFESDLAEIR
 ADKQNL EAILHSLPEN CASWQ

1 cccgcaggg gaaggcgggt cctggcggcc agcgcgcggt ccgcgcccac cctagccgac
 61 ggggcgggca gagcgcgcgg cgtcggtgcc cttgaccatg gcggcggctg cgcttctgct
 121 ggggctggcg ctgctggcac cgcgggcggc cggcgcgggc atgggcgcgt gctatgacgg
 181 cgcagggcgc ccgcagcgt gcctgccggt gtgcgagaa gcggcggttg ggcggctcgc
 241 ccaggcctcg cacacgtgcg gcagcccgcc cgaggacttc tgtccccacg tgggcgcgcg
 301 gggcgcgggg gctcattgcc agcgtgcga cgccgccgac cccagcgc accacaacgc
 361 ctcctacctc accgacttc acagccagga cgagagcacc tgggtggcaga gcccgccat
 421 ggccttcggc gtgcagtacc ccacctcgt caacatcacc ctcgcctag ggaaggctta
 481 tgagatcacg tatgtgagc tgaagttcca caccagtcgc cctgagagct ttgccatcta
 541 caagcgcagc cgcgcgcgac gcccatggga gccctaccag ttctacagcg cctcctgcca
 601 gaagacctac ggcgggccc agggccagta cctgcgcccc ggcgaggacg agcgcgtggc
 661 cttctgcacc tctgagtta gcgacatc cccgtgagt ggcggaacg tggccttc
 721 caccctggag ggcgggccc gcgcctaca ctcgaggag agccctgggc tgcaggagt

Figure 5A

781 ggacaccagc accgaactcc tcactctct agaccggctc aacacgtttg gggacgacat
 841 cttcaaggac cccaaggtgc tccagtccta ctattatgcc gtgtccgact tctctgtggg
 901 cggcaggtgc aagtgaacg ggcatgccag cgagtgcggc cccgacgtgg caggccagt
 961 ggctgcccgg tgccagcaca acaccaccgg cacagactgt gagcgtgcc tgccttctt
 1021 ccaggaccgc cgtggggccc ggggcaccgc cgaggctgcc cacagtgctc tgcctgcaa
 1081 ctgagtgcc cgtccgagg aatgcacgt tcatggggag ctctccgca gcacaggcca
 1141 cggcgggggc tgtaccact gccgtgacca cacagctggg ccacactgtg agcgtgtca
 1201 ggagaattc tactactggg acccgcgat gccatgccag ccctgtgact gccagtcggc
 1261 aggtcccta cacctcagt gcgatgacac aggcacctgc gcctgcaagc ccacagtgc
 1321 tggctggaag tgtaccgct gtctgcccg gttccactc ctcagtggg gaggtgtcag
 1381 accctgcact tgcaatccg ctggcagcct ggacacctgt gaccccgca gtggcgctg
 1441 cccctgcaa gagaatgtg aaggcaacct atgtgacaga tctgcccg ggaccttaa
 1501 cctgcagccc cacaatccag ctggctgcag cagctgttc tctatggcc actccaaggt
 1561 gtgcgctgc actgccagt tccaggtgca tcatctctc agcgatttc accagggagc
 1621 cgaaggctgg tgggccagaa gtgtggggg ctctgagcac tcccacaat ggagccaaa
 1681 tgggtctct ctgagcccag aagacgagga ggagctaca gcaccaggga agttcctggg
 1741 agaccagcg ttcagctatg ggcagccct catactgacc ttcgggtgc ccccgggga
 1801 ctccctact cctgtacagc tgaggctgga agggacaggc ttggcctgt cctgaggca
 1861 ctctagcctg tctggcccc aggatgccag ggcacccag ggaggtagag ctcaggttc
 1921 actgcaggag acctccgagg acgtggcccc tccactgcc ccttccact tccagcggt
 1981 cctgccaac ctgaccagc tccgctccg cgtcagtcg gggccagcc ctgcccgtc
 2041 agtgttctg actgaggtcc ggctcacat cggccggcca gggcttcc cggcagcct
 2101 ctgggtggg attgttcat gtccactgg ctacacggg cagtctgtg aatcctgtg
 2161 tccgggatac aagagggaga tgcacaggg gggctccat gccagctgtg tccctgcac
 2221 ctgaaccag catggcacct gtgacccaa cacagggatc tgtgtctga gccaccatac
 2281 cgaggggcca tctgtgaac gctgttgc aggtttctat ggcaacctt tgcggggcca
 2341 agccgagcag tgcagccct gtccctgcc tggcagtcg gcctgtacga ccatccaga
 2401 gagcggggg gtgtgtgta cccactgcc cccgggccag agaggggcg gctgtgaggt
 2461 ctgtgatgat ggctttttg gggacccgt ggggctctt gggcaccgcc agccctgcca
 2521 ccagtgccag ttagcggga acgtggacc caatgccgtg ggcaactgtg acccctgtc
 2581 tggccactgc ctgcgtgcc tgcacaacac caggggtgac cactgtgagc actgtcagga
 2641 aggttctac gggagcgccc tggccctcg acccgagac aaatgcatg cttgcagctg
 2701 taccacacag ggctcgtga gtgagcagat gccctgcgac ccagtgcag gccaatgctc
 2761 ctgctgctt catgtactg caggggactg cagcgtgc taccctggt tcttcacct
 2821 ccagcctggg aggggctgcc ggagctgcaa gtgtaccca ctgggctccc aggaggacca
 2881 gtgccatccc aagactggac agtgacctg ccgccaggt gtacaggcc aggcctgtga
 2941 caggtgccag ctgggtttt tgggtctc aatcaagggc tgcgggctt gcaggtgctc
 3001 cccactgggc gctgcctcg cccagtgcc ctatacggc acatgctgt gcaggcctgg
 3061 ctgcagggc tacaatgtg accgtgcc ctacaactt tctctacgg cagacggcac
 3121 acactgccag caatgtccg cctgtacgc cctgtgaag gaggagacag ccaagtgaa
 3181 ggccagactg actttgacg aggggtggct ccaagggtcc gactgtgca gtccctggg
 3241 accactagac attctgtgg gagaggcccc aaggggggac gtctaccagg gccatcacct
 3301 gctccaggg gctcgggaag ccttctgga gcagatgat ggctcgagg gtgtgtcaa
 3361 ggccggccgg gagcagctg agagggtgaa caagggtgcc cgtgtgccc aggcggatc
 3421 ccagaagacc tgcaccagc tggcagacct ggaggcagtg ctggagtct cggaagagga
 3481 gattctgat gcagtgcca ttctcgctc tctggagatt cctcaggaag gtccagtca

Figure 5B

INTERNATIONAL SEARCH REPORT

Inter application No.
PCT/US01/18948

A. CLASSIFICATION OF SUBJECT MATTER		
IPC(7) : Please See Extra Sheet.		
US CL : Please See Extra Sheet.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
U.S. : 514/2, 8, 12; 455/825, 471, 68.1, 252.3, 320.1, 71.1, 71.2; 590/412		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
NONE		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
Please See Extra Sheet.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,610,031 A (BURGESON ET AL) 11 March 1997 (11/03/97), see entire document.	1-22
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family	
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search	Date of mailing of the international search report	
09 AUGUST 2001	26 SEP 2001	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3280	Authorized officer PREMA MERTZ Telephone No. (703) 308-0196	

INTERNATIONAL SEARCH REPORT

Intern: . application No.
PCT/US01/13943

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

C07K 1/14, 14/47, 14/475; A61K 38/16, 38/17, 38/18; C12N 5/10, 15/12, 15/63, 15/64

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/2, 8, 12; 435/325, 471, 69.1, 252.3, 320.1, 71.1, 71.2; 530/412

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST, CAS ONLINE, CAPLUS, MEDLINE

search terms: laminin-15, laminin alpha5, laminin beta5, laminin gamma5, recombinant production, isolation, administration, therapy, method, implant, photoreceptor, photosensitivity